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Melanoma is the deadliest form of skin cancer, resulting in over 9,000 deaths annually in 
the United States alone. Along with limiting ultraviolet exposure, it is vital that new 
therapies are generated that target melanoma progression. A recent interest in targeting 
store operated calcium entry (SOCE) as a treatment for different cancers types has 
recently emerged. SOCE is the main mechanism by which non-excitable cells import 
calcium (Ca2+) from the extracellular space and this process is critical for normal growth, 
proliferation, and migration in a variety of cell types. Several studies have demonstrated 
that knockdown or complete genetic deletion of SELENOK reduced SOCE in immune 
cells and retarded their ability to differentiate, proliferate, and migrate. However, the 
effect of inhibiting SELENOK in cancer has not yet been investigated. We hypothesized 
that deletion of SELENOK in melanoma cells may decrease their ability to proliferate 
and metastasize by a reducing SOCE. This hypothesis was tested using three approaches 
(i) SELENOK null mice were crossed with a murine model of melanoma, and melanoma 
progression in the absence of SELENOK was observed, (ii) SELENOK null melanoma 
cells were generated using a CRISPR-Cas9 approach in a human melanoma cell line, and 
tested for their ability to proliferate and migrate in vitro, and, (iii) an inhibitor based on 
the structure of SELENOK was generated and tested for its ability to inhibit the 
SELENOK mediated palmitoylation in a cell free environment. The data presented herein 
show that SELENOK deletion inhibited calcium flux and calcium dependent signaling in 




Furthermore, SELENOK deletion decreased primary growth and metastasis of tumor 
cells in a spontaneous mouse model of melanoma. Last, the inhibitor based on 
SELENOK was shown to be able to disrupt SELENOK mediated palmitoylation and thus 
may serve as a basis for future inhibitors. This dissertation will attempt to outline the data 
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Selenium (Se) is an essential trace mineral fundamental to human health and biology [1]. The 
biological effects of Se are exerted through its incorporation into the 21st amino acid 
selenocysteine (Sec), the defining component of selenoproteins [2] . There are 25 selenoprotein 
family members in humans that perform a wide variety of functions including the regulation of 
redox tone, control of reactive oxygen species, regulating thyroid hormone metabolism, 
facilitating sperm maturation, and promoting optimal immunity [3]. Many of the selenoproteins 
family members exhibit a common thioredoxin-like fold within their catalytic domains with a 
conserved Cys-X-X-Sec (CXXU) or Cys-X-X-Ser (CXXS) motfi [4, 5]. Additionally, many of 
these selenoproteins perform well defined catalytic activities (e.g. glutathione peroxidases, 
iodothyronine deiodinase, thioredoxin reductases, methionine sulfoxide reductases), while other 
selenoproteins do not contain the thioredoxin-like fold and whose functions are relatively 
unknown (e.g. selenoproteins M, T, O, V) [6] . Selenoprotein K (SELENOK) does not contain a 
CXXU motif nor does it appear to catalyze redox reactions. SELENOK is proposed to be an 
intrinsically disordered protein [7] which suggests its function is dependent on a partner protein 
with which it complexes. Intrinsically disordered proteins serving as docking platforms for 
signaling molecules or binding partners has been previously established for other nonenzymatic 
proteins [8]. Indeed, a great deal of what has been discovered about SELENOK function has 
been gained by examining its binding partners [9-11]. This chapter provides a summary of what 












Dietary Selenium and human health   
 
A short summary of dietary selenium and its impact on human health is useful here. Se enters the 
food web via vegetation which acquire it from the soil, and thus Se deficiency has been 
identified in parts of the world with low soil Se content. An example of this is certain regions 
with recent volcanic deposits such as in the Pacific Northwest [12] and large swaths of land in 
the Se-poor belt in Central China [13]. Human Se deficiency is associated with Keshan Disease, 
a cardiomyopathy and Keshin-Beck Disease, which causes severe arthritis [14]. Selenium exerts 
its biological effects via its incorporation into selenocysteine (Sec), which is a component of all 
selenoproteins, some of which perform vital enzymatic functions [1]. Se is found in high 
abundance in the liver spleen, and lymph tissue. Furthermore, Se levels affects cell mediated 
immunity, humoral immunity, and cytotoxicity [15]. In general, Se deficiency in animals leads to 
a less responsive immune system which Se supplementation can reverse [15]. For example, Se 
supplementation in Se-deficient individuals can enhance proliferation of T cells (clonal 
expansion), enhanced response to antigen challenge, and increased ability of T cells to 
differentiate into cytotoxic T cells and kill tumor cells [16]. The mechanism by which Se 
enhances T cell activity may be due in part by the ability of Se to upregulate receptors that 
regulate their growth such as interleukin-2 (IL-2) receptor [17]. Se affects other components of 
the immune system in various ways that will be described below.  
 
Viral Infection  
 
As mentioned previously, Keshan Disease is a prevalent cardiomyopathy that mostly affects 
individuals in Se-poor areas in China. Keshan Disease may be due in part to coxsackievirus 
(CVB3) in which the harmless virus can become virulent under Se-deficient conditions during 
infection [18]. Se supplementation can not only enhance antiviral immunity against CVB3 but 
also prevents oxidative damage to the viral genome that can increase the virulence of CVB3 [18]. 




passaged into Se-adequate mice. If increased virulence is due to viral replication under Se-
deficient conditions, then the Se-adequate mice would not be protected from the passed virus and 
will develop myocarditis. Indeed, the mice inoculated with CVB3 from Se-deficient mice 
developed myocarditis, which was not observed in mice inoculated with CVB3 isolated from Se-
adequate mice [18]. Sequencing of the viral genome of CVB3 isolated from Se-deficient mice 
showed six point mutations that may contribute to their increased virulence, but the mechanism 
by which these mutations lead to increased virulence is unclear [18].  Similarly, studies utilizing 
mouse models of infection with influenza A demonstrate that this virus undergoes increased 
mutational changes in genomic RNA under Se-deficient conditions [19].  
 
Se is critically involved in the etiology of human immunodeficiency virus-1 (HIV-1) infected 
individuals and acts as an inhibitor of HIV replication [20]. Specifically, Se supplementation 
increases glutathione peroxidase activity and thus decreases aberrant NF-kappa B activation by 
H2O2 in HIV-1 infected cells [20]. HIV-1 progression, including the onset of acquired 
immunodeficiency syndrome (AIDS), is caused by a progressive decrease in CD4+ T cells, 
which is paralleled by a decrease in Se plasma levels [21-24]. Furthermore, low Se serum 
concentration ([Se]) in HIV-1 infected patients is associated with increased disease progression 




Epidemiological studies, performed since the 1970s, examining the relationship between Se 
intake and cancer mortality have demonstrated a protective role for Se in cancer progression [27-
29]. The Nutritional Prevention of Cancer (NPC) Trial observed 1321 subjects with a history of 
skin cancer that were supplemented with either 200 µg Se/day (Se-yeast) or placebo. Subjects 
receiving Se supplementation demonstrated 50% less total cancer related mortality, 37% less 
total cancer morbidity, 46% fewer cancers of the lung, 58% fewer cancers of the colon, and 63% 
percent less cases of prostate cancer [30]. The NPC Trial was undertaken in a region where 
selenium uptake by the general population already exceeded the levels required to optimize 




the anticancer effects observed with above normal levels of selenium intake may be due to 
production of antitumorigenic metabolites or enhanced immune response [32]. On the other 
hand, studies have shown the inefficacy of selenium supplementation in inhibiting the 
progression of cancer [33, 34]. Indeed, a study of syngeneic mesothelioma by Rose et al., which 
utilized immune competent mice, demonstrated accelerated tumor progression in mice fed a 
higher selenium diet due to the increased reducing capacity of the tumor cells themselves [35]. 
The often confounding results listed above underscores the importance of the ability to discern 
the effects of the bioavailability of Se on the cancer cells themselves, versus the antitumorigenic 
effects that Se may be exerting via the immune system and the prevention of genetic alterations 
in healthy cells.  
 
Selenoptrotein K structure 
 
SELENOK is a small (94 amino acids), integral, single-pass transmembrane protein localized to 
the endoplasmic reticulum (ER) with a canonical ER retention motif specific for ER 
transmembrane proteins (KKXX) located on the cytosolic side: KKRR. The Sec residue is 
located near the C-terminus at residue 92 (Figure 1.1A). The currently known topological data 
classifies SELENOK as a type III transmembrane protein whereby the N-terminus is luminal. An 
online protein folding modeler was used to generate the predicted tertiary structure of 
SELENOK, which is in agreement with the current topological data (Figure 1.1B) [36]. The 
cytosolic portion of SELENOK contains an abundance of proline and glycine residues and, for 
the most part, has been predicted to be intrinsically disordered (lacking a clear fixed or ordered 
three-dimensional structure).  However, some features have been elucidated from 
experimentation; a calpain cleavage site (aa 81-82), a Src Homology 3 (SH3) binding domain 
(SH3BD) with the canonical consensus motif (R/K-X-X-P-X-X-P), along with possible 
glycosylation and phosphorylation sites. There is evidence that SELENOK can form an 
intermolecular diselenide bond and therefore, at minimum, may exist as a homodimer [69]. 
However, this has only been observed in SELENOK containing micelles and SELENOK 







SELENOK mRNA and protein are widely expressed throughout mouse tissues, although 
particularly high levels have been observed in lymphoid tissue and the testes [37]. Initial studies 
using Northern blot analysis revealed relatively high SELENOK mRNA expression in the heart 
[38], but this has not been supported by additional studies. SELENOK protein expression was 
shown to be positively correlated with increasing Se intake in mice (from 0.25 to 1.0 ppm) by 
western blot detection of all tissues examined except for the heart [39]. Dietary [Se] regulates the 
expression of selenoproteins at the mRNA and protein levels. Under low Se conditions, the 
translation of selenoproteins stall at the Sec-encoding UGA codon and both the mRNA and the 
truncated protein are degraded through nonsense-mediated decay and destruction via C-end 
degrons, respectively [40, 41] .  
 
Dietary [Se] affects expression levels of different selenoproteins to varying degrees [42] and one 
can rank order the least to most Se sensitive selenoproteins in a “hierarchy of selenoproteins” 
[42, 43]. This hierarchy is tissue and cell line specific, often making it difficult to discern to 
discern its nature experimentally. However, differences between selenoproteins in sensitivity to 
limiting [Se] was first demonstrated by experiments comparing the activities of glutathione 
peroxidases 1 and 4 (GPX1 and GPX4) in rat liver, kidney, and heart [44]. Under Se deficiency, 
GPX1 activity was sharply reduced while GPX4 activity was maintained. Furthermore, different 
tissues demonstrated various levels of activity between the two GPXs, confirming the tissue 
dependent aspect selenoprotein Se sensitivity. Finally, in addition to tissue specific Se 
sensitivity, sex also influences the selenoprotein hierarchy [45]. 
 
SELENOK may be involved in regulating ER stress 
 
The ER is essential for proper cellular activities such as protein maturation, lipid synthesis, 
detoxification, and transport of secreted and membrane proteins. Importantly, tightly controlled 
protein folding takes place in the ER and misfolded proteins undergo ER-associated degradation 




stress that can eventually lead to apoptosis [46]. Therefore, ER homeostasis must be tightly 
regulated and may involve one or more of the ER-resident selenoproteins; type 2 iodothyronine 
deiodinase and selenoproteins F, K, M, N, S, and T [47]. The gene encoding SELENOK contains 
a functional ER stress response element and SELENOK has been shown to play an important 
role in protecting HepG2 cells from ER stress-induced apoptosis [5]. Furthermore, SELENOK 
has been shown to participate in ERAD specifically by binding to an ERAD complex with other 
proteins such as Derlin-1 [11]. Along with another selenprotein, selenoprotein S (SELENOS), 
SELENOK participates in ERAD by recruiting cytosolic valosin-containing protein (VCP/p97) 
to promote translocation of misfolded proteins from the ER lumen [9]. It remains unclear how 
the Sec residue may or may participate in retrograde translocation of misfolded proteins and, in 
SELENOK knockout (KO) mice, there are no apparent signs of ER stress [37, 48]. The latter 
finding suggests some redundancy or compensation, perhaps involving SELENOS, may occur in 
the absence of SELENOK expression to mitigate ER stress. 
 
SELENOK is involved in immunity and Calcium Flux rom the ER  
 
A major finding from experiments performed in immune cells from SELENOK KO mice 
suggested a role for SELENOK in immunity and receptor-mediated Ca2+ flux. SELENOK KO 
mice are fertile and healthy with no obvious phenotype [37]. Similarly, development of the 
immune system (total cell and proportion of sub-types) was not affected in SELENOK-deficient 
mice compared to wild type (w.t) controls. However, certain immune dysfunctions were 
observed when mice were challenged with immunogenic agents. Treatment of mice with poly 
(i:c) resulted in lower levels of monocyte chemoattractant protein-1 (MCP-1) and KC chemokine 
production and lower levels of neutrophil infiltration compared to w.t. control groups [36]. 
SELENOK KO macrophages secreted lower levels of interleukin-6 (IL-6) and tumor necrosis 
factor alpha (TNFα) in response to lipopolysaccharide (LPS) challenge and SELENOK KO 
macrophages exhibit decreased oxidative burst after phagocytosis via the Fcγ receptor [36]. 
SELENOK KO mice infected with West Nile virus (WNV) demonstrate a decreased ability to 
clear the virus, were more susceptible to the resulting neuropathology caused by prolonged viral 




macrophages, and neutrophils from SELENOK KO mice demonstrated reduced migration after 
treatment with chemotactic compounds compared to w.t. controls [36]. Finally, receptor 
mediated calcium flux was impaired in SELENOK-deficient T cells, macrophages, and 
neutrophils after stimulation with chemokines and other reagents that trigger G-coupled protein 
receptor signaling in these immune cells [36]. 
 
The calcium mediated immune deficiencies observed in the SELENOK KO mice may be due to 
deficient store-operated calcium entry (SOCE) in immune cells. SOCE is a specifically defined 
set of events by which non-excitable cells import extracellular calcium into the cytosol, induce 
Ca2+ dependent signal transduction, and replenish their calcium stores [49, 50]. SOCE is initiated 
when various receptor plasma membrane receptors (G-coupled protein receptors, tyrosine 
kinases, Fcγ receptors, T cell receptors) are engaged by their respective ligands, leading to 
phospholipase C (PLC) activation which cleaves phosphatidylinositol 4,5 bisphosphate (PIP2) 
into Inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to the inositol 
trisphosphate receptor (IP3R) and leads to Ca2+ efflux from the ER into the cytosol, down its 
electrochemical gradient. This loss of Ca2+ is sensed by stromal interaction molecule 1 (STIM1) 
which oligomerizes and translocates to ER PM junctions termed puncta and interacts with Orai 
Ca2+ calcium channels and allows Ca2+ to enter the cytosol from the extracellular space [51]. 
Evidence that SELENOK promotes SOCE was obtained in subsequent investigations, revealing 
that SELENOK acts as a co-factor, along with the acyl transferase DHHC6, to catalyze the 
palmitoylation of the IP3R, allowing for its proper expression in the ER membrane [52]. The 
details of these findings are described in more detail below.  
 
The role of SELENOK in promoting protein palmitoylation  
 
Investigation into the role that SELENOK plays in immune system activation during 
atherosclerosis revealed that SELENOK was required for lipid raft localization of the oxidized 
low density lipoprotein receptor, CD36, on macrophages [53]. SELENOK-deficient 
macrophages were found to have decreased CD36 palmitoylation, which is crucial for stabilizing 




residues is a post translational modification that promotes the anchorage of integral and 
peripheral proteins in the membrane, and also modulates hydrophobic protein-protein 
interactions [55]. Subsequent studies found that palmitoylation of other proteins required 
SELENOK including Arf-GAP with Src homology 3 domain, ankyrin repeat, and plekstrin 
homology domain-containing protein 2 (ASAP2) and the IP3R (Figure 1.2) [10, 56]. There are 
very likely other proteins that require SELENOK for protein palmitoylation. As alluded to 
above, S-palmitoylation is the addition of the 16-carbon fatty acid, palmitate, to cysteine residues 
on target substrate proteins via a thioester bond [57]. Since SELENOK itself is not an enzyme it 
must bind to a partner enzyme to promote palmitoylation. A major clue to help identity the 
enzymatic binding partner of SELENOK was the fact that SELENOK is the only selenoprotein 
with an SH3 binding domain and one member of the enzyme family involved in palmitoylation 
reactions contained an SH3 domain. Indeed, SELENOK interacts with the protein acyl-
transferase (PAT), DHHC6 (letters represent the amino acids aspartic acid, histidine, histidine, 
and cysteine in the catalytic domain), in the ER membrane through SH3/SH3BD interactions and 
this is how SELENOK participates in palmitoylation reactions [10]. 
 
The specific mechanism by which SELENOK exerts its effects on DHHC6 to increase its 
catalytic efficiency required new tools to be built so that the enzymatic reaction of acyl transfer 
could be examined in more detail. The palmitoylation reactions catalyzed by DHHC enzymes 
have been shown to proceed via a two-step mechanism [58] (see Chapter 3 for more details on 
DHHC family). In the first, so-called autopalmitoylation step, a Cys residue within the DHHC 
catalytic domain reacts with palmitoyl-CoA to form a palmitoyl-PAT intermediate. In the second 
step, the palmitoyl group is transferred from the PAT to a Cys residue on the target protein. The 
first step is rapid, whereas the second is much slower. Thus, after the first step, the unstable 
thioester bond between Cys on the PAT and the palmitic acid may hydrolyze before transfer of 
the palmitic acid to a target protein, termed the “futile cycle” [59]. The Hoffmann laboratory was 
able to synthesize soluble versions of DHHC6 and have shown that it can bind recombinant 
SELENOK in a complex that exhibited acyl transferase activity. The data from these 
experiments showed that SELENOK increases the catalytic efficiency of palmitoylation by 




the futile cycle [60]. This binding of a PAT enzyme with a cofactor to promote intermediate 
stabilization was previously found in another protein pair in yeast. In particular, the yeast 
ethylene-responsive factor-2 (Erf2) is an ortholog for mammalian DHHC9 and binds to yeast 
ethylene-responsive factor-4 (Erf4) in a manner that stabilizes the acyl-Erf2 intermediate and 
increases its catalytic efficiency [61]. Erf4 is not a selenoprotein (yeast do not express 
selenoproteins), so the manner in which these two cofactors increase catalytic efficiency must 
necessarily be different. As discussed below in more detail, the Sec residue in SELENOK plays a 
critical role in promoting palmitoylation. 
 
The Sec residue in SELENOK is responsible for its bioactivity 
 
To understand the importance of the Sec residue in SELENOK it is necessary to differentiate its 
chemical properties from the amino acid most similar to Sec, cysteine (Cys). Sec and Cys are 
structurally identically except for a selenium atom in Sec in place of the sulfur atom in Cys. The 
pKa of the thiol in free Cys in 8.5 whereas the pKa of the selenol in free Sec is 5.7 [62]. Thus, 
Sec is more likely to be anionic under physiological conditions and exhibits superior 
nucleophilic reactivity compared to Cys [63]. Sec containing proteins are less likely to be 
irreversibly oxidized compared to cysteine containing proteins due to the propensity of selenic 
acid to be readily reduced compared to sulfinic acid [63]. Irreversibly oxidation of Cys can cause 
enzymatic inactivation and therefore, Sec containing enzymes may be more resistant to oxidative 
inactivation because of their ability to cycle through oxidation states much faster compared to 
Cys containing enzymes [63, 64]. The enhanced nucleophilic reactivity and the resistance to 
enzymatic inactivation by oxygen may explain why Sec containing oxioreductases, such as 
thioredoxin reductase, methionine sulfoxide, and glutathione peroxidase are 100- to 1,000-fold 
more active compared to their Cys mutated counterparts [65-68]. The observations listed above 
may help to explain the experimental evidence that show the requirement of the Sec residue for 
the bioactivity of SELENOK.  
 
The Sec residue in SELENOK is located near the C-terminus (amino acid 92), which is a feature 




been shown to exhibit some antioxidant activity in vitro [38, 70] a role for regulating redox 
reactions in in vivo has yet to be established. Indeed, SELENOK does not contain defined redox 
motifs such as those observed in glutathione peroxidases or thioredoxin reductases and ER stress 
not observed in SELENOK-deficient mice [37]. As described above, SELENOK KO mice were 
observed to have impaired SOCE in T cells, neutrophils, and macrophages when stimulated with 
chemokines and other reagents that trigger receptor mediated signaling in these immune cells 
[37].  Importantly, when these immune cells were stimulated with thapsigargin, a drug that 
induces SOCE in a manner that bypasses the IP3R, the w.t. and KO cells did not differ. This 
implicated the IP3R as a molecule somehow involved in SELENOK-dependent SOCE. 
 
The exact mechanism by which SELENOK regulated SOCE was not initially clear, but the 
requirement of the Sec residue in this process became evident when it was observed that a 
calpain protease (calpain-2), that cleaved the C-terminal end of SELENOK (residues 81-94, 
including Sec92) from the remaining protein, abolished the SOCE promoting activity of 
SELENOK [71].  Interestingly, resting macrophages actively cleave SELENOK via calpain-2 to 
maintain low levels of calcium flux. However, when macrophages are activated, the endogenous 
inhibitor of calpains, calpastatin, is upregulated, which allows full-length SELENOK to be 
expressed. Expression of full length SELENOK can then lead enhanced IP3R mediated calcium 
flux and turn on cellular programs related to active macrophage function. In this sense, dietary 
Se along with the calpain-2/calpastatin system are both regulators of SELENOK function. In 
fact, the endogenous inhibitor of calpain-2, calpastatin, protects SELENOK from cleavage and 
thereby serves as a positive regulator of SELENOK function [71, 72]. Dietary Se levels regulate 
the levels of Sec incorporation into SELENOK while calpain-2 regulates cleavage of the 
functional domain. To date, no other selenoproteins have been described as being proteolytically 
modulated by calpain enzymes, although investigations into this issue have not been extensive. 
 
The definitive experiments showing the requirement of the Sec residue at position 92 of 
SELENOK for its function were recently published [60]. Recombinant versions of SELENOK 
containing either Sec92, Cys92, or Ala92 complexed to a soluble version of DHHC6 were used in 




catalytic efficiency of DHHC6, while Cys92 or Ala92 were equally insufficient to allow 
SELENOK to increase the catalytic efficiency of DHHC6. As mentioned above, selenoester 
bonds have been shown to have high reactivity in acyl transfer reactions [73]. This is consistent 
with the Sec residue in SELENOK being particularly suited to combine with DHHC6 for 
catalyzing protein palmitoylation as an important post-translational modification, and the fact 
that our studies showed that Sec cannot be replaced with Cys for protecting the thioester bond in 
the acyl-DHHC6 intermediate from hydrolysis. The role SELENOK plays in palmitoylation 
reactions and how it is regulated are illustrated in Figure 1.3. 
 
SELENOK in cancer  
 
There is a paucity of information on the exact role that SELENOK plays in carcinogenesis or 
tumor progression. However, the effects of SELENOK loss-of-function or gain-of-function in 
different tumor lines have been studied. For example, knockdown of SELENOK in human 
choriocarcinoma cells enhanced the proliferative, migratory, and invasive capacity of these cells, 
while over-expressing SELENOK had the opposite effect [74]. Similarly, overexpression of 
SELENOK in human gastric cancer BGC-823 cells reduced cell adhesion and migration [75]. 
Micro RNAs may also regulate SELENOK levels in certain cancers [76] and this may be cancer 
type specific or even vary between the cancer cell population within tumors.  Given that 
SELENOK forms complexes with other proteins in order to exert it biological functions, 
manipulating the levels of SELENOK may alter the stoichiometry of the members within these 
complexes. Therefore, it may be that alterations in SELENOK expression that alter the optimum 
level within the complexes can disrupt functions required by different cancer cells at various 
stages, or different immortalized cell lines at different stages.  
 
In a study assessing if the risk of prostate cancer is affected by polymorphisms in the gene 
encoding SELENOK, it was found that if Se status was taken into account, that a single 
nucleotide polymorphism (SNP) of SELENOK, located in the promoter region of the gene, is 
associated with advanced stage or high-grade disease risk [77]. Whether this SNP of SELENOK 




based on the complex relationship between SELENOK and cancer, therefore more physiological 
models of SELENOK and cancer are needed.  
 
The subsequent chapters present the results of our attempt to elucidate the role of SELENOK in a 
model of cancer with the following specific objectives: (i) determine the in vivo effects of 
SELENOK deficiency on primary melanoma tumor progression and metastasis, (ii) determine 
the mechanisms by which SELENOK affects melanoma cell proliferation, migration, and colony 



































Figure 1.1 Predicted structure of SELENOK. (A) Schematic showing primary amino acid 




domain, a calpain cleavage site between residues 81 and 82, a proline rich SH3 binding domain 
(SH3BD), and a single Sec residue at amino acid position 92. (B) Predicted protein folding 
model was for SELENOK was generated using Phyre2 online protein fold recognition server and 
EzMol was used to generate protein display and image production. Red area represents the SH3 
binding domain, orange area represents the transmembrane domain, and the green area represents 





Figure 1.2 SELENOK/DHHC6 is necessary for palmitoylation and expression of the IP3R.  
Model demonstrating SELENOK and DHHC6 interacting via SH3/SH3BD (SH3 binding 
domain) motifs and subsequent transfer of palmitate to the IP3R, resulting in the stable 







Figure 1.3 SELENOK stabilizes the DHHC6 palmitoylated intermediate and enhances 
palmitoylation of DHHC6 target. DHHC6 palmitoylates its targets protein in a two step-
process: 1) DHHC6 is auto-palmitoylated in the presence of palmitoyl-CoA, and 2) the palmitate 
group is transferred to a DHHC6 target. MGCDRNCK represents the palmitoylation 
consequence sequence on the N terminus of CD36. SELENOK may prevent hydrolysis (futile 



















Chapter 2. Selenoprotein K deficiency inhibits melanoma by decreasing cytosolic 




Ca2+ is a ubiquitous signaling cation and a widely used secondary messenger that is critical to a 
variety of cellular processes. The primary store of intracellular Ca2+ is the ER, and cytosolic Ca2+ 
concentration is maintained at nanomolar levels by plasma membrane Ca2+ ATPases and SR/ER 
Ca2+ ATPases that pump Ca2+ into the extracellular space and the ER lumen respectively [78]. 
Activation of various surface receptors activates phospholipase C that subsequently hydrolyzes 
phosphatidylinositol 4,5-bisphosphate into diacylglycerol and inositol 1,4,5-trisphosphate (IP3). 
IP3 is an agonist of ER-membrane IP3 receptors (IP3Rs) and ligand engagement results in Ca2+ 
release from the ER lumen, which is sensed by the EF-hand motif of stromal interaction 
molecules (STIM1 and STIM2) within the ER [79]. This induces STIM1 to oligomerize and 
translocate to ER-plasma membrane junctions where it interacts with Orai Ca2+ calcium channels 
and allows Ca2+ to enter the cytosol from the extracellular space [51]. This process is termed 
store operated Ca2+ entry (SOCE) [80] and is the primary mechanism by which non-excitable 
cells utilize for activating Ca2+ dependent signaling cascades that are required for cellular 
functions such as proliferation and migration [49].  
 
When healthy, normal cells transform into malignant tumor cells Ca2+ homeostasis and signaling 
may be altered in a process referred to as Ca2+ remodeling [81]. SOCE and the downstream Ca2+ 
dependent signaling cascades, are exploited by cancer cells to increase their capacity to 
proliferate, migrate, and survive. Because SOCE is important for both primary tumor growth and 
metastasis to other sites, molecules regulating SOCE are logical targets for developing anti-
cancer therapeutics [82, 83]. However, little is known regarding the targetable mechanisms that 
drive SOCE in malignant melanoma. Therefore, there is a need to elucidate the extent to which 





SELENOK is a member of the selenoprotein family, of which there are 25 members in humans, 
that each contain the 21st amino acid, selenocysteine. SELENOK is an ER transmembrane 
protein that regulates IP3R driven Ca2+ flux [37]. Expression levels of SELENOK are regulated 
by dietary selenium [37, 84] and its function is regulated in in some cell types by calpain 
cleavage [71]. The mechanism by which SELENOK regulates Ca2+ flux is its role as a cofactor 
that binds to the acyl transferase, DHHC6, to catalyze the palmitoylation of the IP3R [52]. In the 
absence of SELENOK/DHHC6 catalyzed addition of palmitate to the tetrameric IP3R, Ca2+ 
release from the ER is impaired [10]. The following chapter provides evidence that SELENOK is 
indeed necessary for effective Ca2+ flux in human melanoma cells and SELENOK deficiency 
reduces their growth and stemness properties, leading to reduced proliferation and migration in 


























Melanoma is a malignancy that arises in the melanocytes present in the basal layer of the 
epidermis. Although Melanoma comprises of only 4 percent of all skin cancers, it is responsible 
for 80 percent of deaths in all dermatological cancer [85]. The 10-year survival rate for patients 
with late stage metastatic melanoma has been estimated to be as low as 7 percent [85]. The Clark 
Model of Melanoma was established in the 1970s and describes the stepwise transition of 
melanocytes to malignant melanoma with the following six steps of tumor progression: 1) 
acquired melanocytic nevus (mole); 2) a melanocytic nevus with proliferation into the basal layer 
of the epidermis; 3) a melanocytic nevus with aberrant differentiation and abnormal appearance 
of cell nuclei; 4) radial growth of primary melanoma; 5) vertical growth of primary melanoma; 
and 6) metastatic melanoma. A genetic basis of melanoma progression has been established 
based on the Clark model [85, 86]. The acquisition of melanocytic nevi frequently express 
activating BRAF mutations [85] followed by a temporary cessation in proliferative activity.  
 
The next step in the evolution of melanoma, involving the proliferation of transformed cells into 
the basal layer of the epidermis, may involve the inactivation of CDKN2A. This is supported by 
the observation that 25-40 percent of patients with familial melanoma (and develop dysplastic 
nevi) have germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A) [87]. The 
radial expansion of melanoma, whereby the neoplastic melanocytes invade into the epidermis, is 
associated with the activation of human telomerase reverse transcriptase (hTERT) [88]. Finally, 
vertical growth of primary melanoma and the ability of transformed melanocytes to metastasize 
and colonize distant tissues involve various mutations that increase survival, inhibit apoptosis, 
and promote epithelial to mesenchymal transition (EMT). Specifically, loss of phosphatase and 
tensin homolog (PTEN) inhibits apoptosis via AKT activation, constitutive activation of Ras or 





Risk factors and molecular mechanisms of ultraviolet damage response 
 
The risk factors for the development of melanoma include a family history of melanoma, 
multiple benign or abnormal nevi, immunosuppression, sun sensitivity, and exposure to 
ultraviolet (uv) radiation [90]. Each risk factor has a variety of environmental and genetic 
detriments that are not mutually exclusive. For example, sensitivity to uv light is associated with 
polymorphisms that affect the risk of developing melanoma, particularly polymorphisms within 
the alleles encoding the melanocortin receptor 1 (MC1R) and genes involved in nucleotide 
excision repair (NER) [91]. The importance of NER is clear in the case of patients with 
Xeroderma Pigmentosum (XP), a rare disorder exemplified by uv hypersensitivity syndrome 
caused by the homozygous deletion in any one of the eight necessary effector proteins that 
execute NER. XP patients exhibit extreme uv sensitivity and develop premalignant lesion and 
skin cancer at a high frequency. While people with XP clearly demonstrate the importance of 
NER in skin cancer prevention, NER polymorphism and skin cancer incidence may contribute to 
skin cancer development, including melanoma, in the general population [91]. uv radiation 
causes genomic damage, such as thymine dimers and the formation of DNA damaging reactive 
oxygen species (ROS) [92]. Molecularly, uv exposure induces the generation of α-melanocyte-
stimulating hormone (α-MSH) MC1R. MC1R engagement by α-MSH leads to the activation of 
adenylyl cyclase which converts ATP to cAMP [93, 94]. cAMP accumulation activates protein 
kinase A (PKA), leading to a variety of downstream events including upregulation of genes 
associated with the production of melanin via the cAMP responsive binding element (CREB) 
[95] and upregulation of genes involved in NER [96, 97]. Therefore, individuals with sub-
optimal MC1R signaling have a higher risk of developing melanoma, not only because their skin 
is under-melanized, but also because they have impaired DNA damage repair mechanisms. 
 
Ca2+ signaling in cancer 
 
Tightly controlled and regulated calcium signaling is necessary for normal cellular functioning 




pumps, channels, exchangers, calcium binding proteins that maintain calcium homeostasis in the 
cell [49, 98]. Cells at rest typically maintain an intracellular Ca2+ concentration ([Ca2+]) of 
approximately 100 nM and a [Ca2+] of 100-800 µM in the ER [99]. The extremely low [Ca2+] in 
the cytosol is necessary for Ca2+ to act as a ubiquitous secondary messenger, allowing the cell to 
“decode” the spatially and/or temporally variable changes in cytosolic free Ca2+ and transduce 
the appropriate signals downstream [98]. When normal cells transform into malignant tumor 
cells, calcium homeostasis and calcium signaling may be altered. Perhaps most simply, protein 
expression of specific Ca2+ channels and pumps can be altered in various cancer types. For 
example, expression studies have identified numerous Ca2+ channels and pumps as potential 
therapeutic targets for brain [100] breast [101], prostate [102], and ovarian cancers [103], 
implying their aberrant expression in these cancers. It should be noted that post-translational 
modifications of the components of calcium signaling may also contribute to Ca2+ remodeling in 
cancer, such as altered Ca2+ pump or channel localization [104]. For example, while not 
occurring in a cancer cell type, phosphorylation of STIM1 inhibits SOCE in endothelial cells and 
may be involved in regulating endothelial permeability responses [105]. 
 
Because SOCE is the major mechanism by which non-excitable cells import calcium from the 
extracellular space and refill their calcium store, many of the calcium signaling tools mentioned 
above are directly involved in SOCE. Recently, an interest in targeting SOCE components as a 
treatment for various cancers has emerged. For example, Yang et al. demonstrated that 
pharmacological blockade or silencing of STIM1 or Orai1 reduced migration and metastasis of 
breast cancer cells [106]. SOCE is also involved in melanoma cell proliferation and migration 
[107], and cell migration, proliferation, and angiogenesis in cervical cancer [108]. This chapter 
will focus on the effects of SELENOK on one of the main components of SOCE, namely the 
IP3R. Therefore, the IP3R and select downstream signaling pathways induced by IP3R mediated 
Ca2+ flux will be discussed in detail. However, because of the ubiquitous nature of Ca2+ 
signaling, many Ca2+ dependent signaling pathways may be affected by reduced Ca2+ flux, but 





Inositol trisphosphate receptor and its regulation 
 
IP3Rs are a family of intracellular ligand-gated Ca2+ release channels localized primarily in the 
ER in almost all cell types [109]. IP3R modulates cytoplasmic free [Ca2+], and thereby is 
involved in the regulation of processes as diverse as learning and memory, synaptic transmission, 
membrane trafficking, motility, cell proliferation, and apoptosis [110]. Modulation of cytosolic 
[Ca2+] via IP3R involves the activation of PLC by a diverse set of cell surface receptors 
including G-coupled protein receptor (GPCRs), receptor tyrosine kinases (RTKs), toll like 
receptors (TLRs), and T cell receptors (TCRs). PLC converts the membrane bound lipid PIP2 
into IP3 and DAG [110]. IP3 diffuses in the cytoplasm and binds to the IP3R at the cytoplasmic 
surface of the ER. The ER is the major calcium storage organelle in most cells and therefore 
opening of IP3R results in calcium movement down its electrochemical gradient from the ER 
into the cytoplasm. Ca2+ release from the IP3R is tightly spatially and temporally regulated by a 
variety of factors such as the availability of Ca2+, binding proteins, and the properties of the 
various isoforms of the (IP3R). This regulation restricts the range of action of Ca2+ to 
approximately 5 µm [111] and enables IP3R mediated Ca2+ signaling to be remarkably specific 
as well as diverse.  
 
The IP3R family (IP3R1, IP3R2, and IPR3) is encoded by three separate genes in vertebrate cells 
[112, 113] where the primary amino acid sequences of the three isoforms share 60-80% sequence 
identity [114]. In mammals, the IP3R is expressed in all cell types [115, 116], and except for the 
central nervous system, each cell type expresses more than one isotype [117]. IP3R1 expression 
is prominent in the brain and cerebellum and IP3R2 expression is prominent in epithelia cells in 
the kidney and heart [118]. IPR3 is highly expressed in the testis and in fibroblast cells [118, 
119]. Cell type dependent, differential expression of IP3R isoforms that differ in cellular 
localization and ligand sensitivity implies that each isoform confers specificity for unique 
cellular processes. For example, each isoform may have different sensitivity to ubiquitin-related 
downregulation after activation via IP3 [120] and numerous studies have demonstrated that the 
IP3 binding affinity differs among the three channel isoforms [121]. However, the hierarchy of 





The IP3R is a tetramer with each subunit having a molecular mass of ~300 kDa [125]. The 
structure of each IP3R molecule consists of a large NH2 terminus (comprises 85% of the 
protein’s mass) localized to the cytoplasm, a hydrophobic, six membrane-spanning regions in the 
ER membrane that forms the ion-conducting pore, and a short cytoplasmic COOH terminus 
[110]. The NH2 terminus contains the IP3 binding domain at residues 226-578 and a regulatory 
domain at residues 586-2276 [110]. Genetic deletions within the regulatory domain result in a 
disruption of channel function [126]. The two major regulators of IP3R function are IP3 and 
Ca2+, both of which can act as co-agonists [127, 128]. IP3 regulation of IP3R can be viewed as 
modulation of IP3R potentiation to [Ca2+]. More specifically, IP3-induced Ca2+ flux is regulated 
in a biphasic manner, resulting in potentiation of the IP3R at low [Ca2+] and inhibition at high 
[Ca2+] for all three isoforms of IP3R [129]. A model has been proposed whereby IP3 binding 
prevents binding of Ca2+ to the regulatory domain and reciprocally, Ca2+ binding of the 
regulatory domain prevents IP3 binding [130]. Additionally, IP3Rs are regulated by 
phosphorylation by numerous protein kinases including PKA, protein kinase B (PKB/Akt), 
protein kinase C (PKC), Ca2+/ CaM-dependent protein kinase II, cyclic-dependent kinases 
(CDKs), Rho kinases, mammalian target of rapamycin (mTor), cGMP-dependent protein 
kinases, and a variety of protein tyrosine kinases [131]. PKB/Akt is a proto-oncogene associated 
in cellular survival and growth [132]. Each of the three isoforms of IP3R have the conserved 
phosphorylation motif RXRXX(S/T) at their C-terminus and phosphorylation at this site 
promotes survival [133, 134]. Furthermore, the antiapoptotic protein Blc-2 has been shown to 
physically interacts with IP3R1 isoform, increasing IP3R1 phosphorylation and calcium flux 
through the IP3R1, thus promoting survival [135]. Pertinent to the data presented in this chapter, 
the IP3R is palmitoylated on three cysteine residues (C56, C849, and C2214), and one or more of 








Mitogen activated protein pathway  
 
The Ras/Raf/MEK (mitogen-activated protein kinase/ERK kinase)/ERK (extracellular-signal-
regulated kinase) pathway is a conserved signaling pathway that governs proliferation, 
differentiation and survival in all eukaryotes [136]. The signaling cascade is activated by a wide 
variety of receptors (RTKs, integrins, and ion channels) and their various ligands (growth 
factors, differentiation factors, and tumor-promoting molecules). In general, a set of adaptor 
proteins such as growth-factor-receptor-bound protein 2 (GRB2) link guanine nucleotide 
exchange factors like son of sevenless (SOS) to the receptors, thereby transducing the signal to 
small GTP-binding proteins (Ras, Rap1). These small GTP-binding proteins activate the main 
component of the cascade composed of a MAPKKK (Raf), a MAPKK (MEK1/2), and MAPK 
(ERK). A phosphorylated/activated ERK dimer can then translocate to the nucleus where and 
phosphorylate a variety of transcription factors regulating gene expression [137].  
 
Dysregulation of the small GTPase Ras or its downstream effectors such as ERK have been 
shown to be critical in the tumorigenesis of many cancer types [138]. In melanoma, activating 
Ras mutations are associated with only 15 percent of cases [85] and are limited to N-Ras [139]. 
While activating Ras mutations are rare in Melanoma, BRAF somatic mutations are associated 
with 50 percent of melanomas which results in constitutive activation of ERK [85]. Mutations in 
N-Ras stabilize the GTP bound form of the protein and thus maintains N-Ras in an activated 
state [140]. Mutations in BRAF occur within the kinase domain and approximately 80 percent of 
them due to a single substitution (V599E) [141]. BRAF mutations occur at similar levels in 
benign nevi and in metastatic melanoma [142]. Because most benign nevi can stay dormant for 
decades, the similarity in observed frequency of BRAF mutations suggest that nevi must acquire 
additional mutations to become malignant, such as loss of tumor suppressors as described in the 







Calcineurin-Calmodulin-NFAT axis  
 
Nuclear factor of activated T cells (NFAT) proteins are expressed in most immune cells and 
promote the transcription of genes vital to the proper functioning of the immune system [143] 
and the proliferation and survival of many other cell types [144]. NFAT activity is regulated by 
the calcium/calmodulin dependent phosphatase calcineurin [144]. Specifically, calcium influx 
from SOCE (described in chapter 1) activates the calcium sensor calmodulin which binds to the 
regulatory domain of calcineurin, causes a conformational change that removes the 
autoinhibitory domain from the active site, which results in the activation of the phosphatase 
[145]. Activated calcineurin then dephosphorylates multiple serine residues near the N-terminus 
of NFAT proteins, revealing a previously masked nuclear localization sequence (NLS) and 
results in the translocation of NFAT from the cytoplasm to the nucleus [146]. Because NFATs 
bind their DNA target sequences with relatively weak affinities, they rely on a variety of 
cooperative transcription factors to enhance binding to promoter regions [147, 148]. Thus, NFAT 
complexes can integrate Ca2+/calcineurin activity, along with additional signals, to result in a 
diverse set of cellular programs, including differentiation, growth, and survival [149]. 
 
Dysregulation of calcineurin/NFAT signaling has been observed in a variety of solid tumors and 
lymphomas [150] and NFAT may be a downstream mediator of oncogenic BRAF in metastatic 
melanoma [151]. NFAT proteins may play an important role in the dysregulation of cell cycle 
control via aberrant Ca2+ signaling. For example, overexpression of a constitutively active 
mutant of NFAT1 has been shown to be sufficient to induce a transformed phenotype in 
preadipocyte 3T3-L1 fibroblasts and is associated with aberrant expression of cell-cycle related 
genes such as pRB, c-myc, cyclin D1, and cyclin D2 [152]. Furthermore, ectopic expression of 
highly activated NFATc1 has been observed in pancreatic cancer cells in vitro that promoted c-
myc generation and thus increased G1/S phase transition in Panc-1 and ASPC-1 cell lines [153]. 
Additionally, NFAT signaling has been implicated in the development of tumors of epithelial 
origin such as colon carcinoma. In the human colon carcinoma cell lines Caco-2, HCT116, and 
HT29, activation of NFAT1 and NFAT2 was shown to induce the transcriptional upregulation of 




angiogenesis, and proliferation [154]. Finally, research in our laboratory has demonstrated that 
inhibiting SOCE in a human melanoma cell line, decreases calcineurin activity and results in less 
NFAT translocation to the nucleus that may impair cellular programs that contribute to 
tumorigenesis (data in results).  
 
Cancer stem cells  
 
Cancer stem cells (CSCs) are a small subset of a tumor population with the indefinite potential 
for self-renewal that drive tumorigenesis [155].  A tumor can be conceptualized as an abnormal 
organ that originated from a tumorigenic cancer cell that that acquired the ability to indefinitely 
proliferate. Viewed from this perspective, fundamental properties of cell biology can be applied 
to the tumor, such as normal stem cell biology. Indeed, although most tumors have a clonal 
origin [156, 157] they contain a heterogeneous combination of cells; this suggests that, akin to 
normal stem cells, tumors contain a specialized cell type that give rise to heterogenous cell 
progeny and can indefinably replicate. Evidence for this theory was first documented when 
mouse myeloma cells, obtained from myelomatous ascites, were tested in an in vitro colony-
forming assay and only 1 in 100 – 10,000 cells were able to form colonies [158]. Furthermore, 
only 1-4% of leukemia cells were able to form spleen colonies when transplanted [159] and a 
small subset of human adult acute myeloid leukemia (AML) cells (0.2%), which could be 
identified as CD34+CD38-, could transfer AML to NOD/SCID mice while other subsets could 
not [160]. Correctly identifying the sub-population of cancer cells that contribute to 
tumorigenesis can lead to more directed therapeutics for treating cancer.  
 
One of the most consistently observed markers of CSCs is prominin 1 (Prom1 or CD133) [161-
164]. Prom1 is a member of the pentaspan transmembrane glycoprotein family [165] and was 
originally discovered as a marker specific for hematopoietic stem cells [166]. Prom1 function is 
mostly unknown, however it is selectively associated with plasma membrane protrusions via 
cholesterol binding [167] and may play a role in the maintenance of retinal photoreceptors [168]. 
Prom1 was associated with and used to isolate brain tumor stem cells (BTSCs) from human 




differentiation [164]. Similarly, Prom1 was shown to be critical for growth and metastasis of 
human metastatic melanoma cells and shRNA knockdown of Prom1 resulted in reduced spheroid 
formation and migratory capacity [169]. Furthermore, microarray analysis of Prom1 knockdown 
FEMX-1 melanoma cells showed upregulation of genes associated with Wnt inhibitors, 
suggesting that Prom1 interacts with the canonical Wnt pathway [169]. 
 
Melanoma tumor cells utilize SOCE for their growth and proliferation similar to what has been 
observed in immune cells. Because genetic deletion of SELENOK in immune cells inhibited 
SOCE it is logical that KO of SELENOK in melanoma tumor cells may reduce their ability to 
grow and proliferate via a similar mechanism. Furthermore, previous investigations undertaken 
by the Hoffmann laboratory demonstrated the necessity of the Sec residue in SELENOK for its 
biological function. Therefore, we utilized two tools to elucidate the role of SELENOK in 
metastatic melanoma: (i) complete KO of SELENOK in a mouse model of melanoma and (ii) a 
CRISPR-Cas9 generated, truncated version of SELENOK that does not contain the Sec residue 
in a melanoma cell line. The effects of SELENOK deletion/truncation on melanoma cells are 



















Loss of functional SELENOK in melanoma cells leads to decreased proliferation 
 
In some cases, but not all, molecular components of SOCE are overexpressed in melanoma 
tumor tissue compared to healthy tissue [170]. Therefore, SELENOK levels in early and late 
stage malignant melanoma tissues from a small group of patients (N = 10) were examined by 
histological analysis and rank ordered from 0 (negative) to 3 (strong signal in at least 25% of 
cells). No differences were found compared to normal control tissue (Figure S2.1). Next, western 
blot analysis was performed to test whether SELENOK protein expression is increased in 
metastatic melanoma cell lines compared to primary melanocytes. SELENOK protein expression 
in three NCI-60 validated human melanoma cell lines (SK-MEL-2, SK-MEL-28, and MALME-
3m) and primary human melanocytes were evaluated and protein expression of SELENOK was 
not significantly increased in the melanoma cell lines compared to primary melanocytes (Figure 
2.1A).  
 
SELENOK is required for the post-translational palmitoylation of the IP3R and its stable 
expression in the ER membrane allows for proper SOCE in immune cells [10]. Previous studies 
have demonstrated that knockdown (KD) of molecules involved in SOCE (e.g., Orai1) resulted 
in decreased migration and proliferation of melanoma cells [107]. Therefore, it is conceivable 
that SELENOK-deficient melanoma cells may exhibit impaired SOCE dependent growth and 
migration. To test this hypothesis, a CRISPR/Cas9 approach was used to generate a functional 
knock-out of SELENOK in the SK-MEL28 cell line with the domain necessary for 
palmitoylation of IP3R removed but with the SH3BD left intact (Figure 2.1B). Preserving the 
SH3BD while truncating the palmitoylation functional domain in SELENOK allows SELENOK 
to interact with DHHC6 but prevents the enhanced palmitoylation efficiency that full-length 
SELENOK provides [52]. This CRISPR/Cas 9 truncated version of SELENOK is similar to the 
calpain cleaved version of SELENOK in resting macrophages [71] and putatively decreases 
palmitoylation of the IP3R by a similar mechanism. Two independent clones were identified and 




(Figure 2.1C). One of these cell lines contained an edited allele encoding a truncated version of 
SELENOK and one unedited allele encoding the full-length version of SELENOK (clone 3) or 
both alleles of SELENOK truncated (clone 7). The western blot results were consistent with 
Sanger sequencing of the clones (Figure S2.2). First, a proliferation assay was performed that 
compared the rates of proliferation of unedited SK-MEL28 cells, clone 3, and clone 7 for four 
days. Clone 3 cells and unedited cells proliferated at comparable rates, whereas clone 7 
proliferation rates were reduced up to approximately 3-fold (Figure 2.1D). This suggests that at 
least one allele of SELENOK is necessary for normal proliferation in SK-MEL28 cells. Next, an 
in vitro model for wound healing was performed to determine if SELENOK truncation would 
reduce the ability of the cells to grow and migrate into the scratched area. These results showed 
that clone 7 cells filled the scratched area to a significantly lower degree compared to unedited 
cells and clone 3 cells (30 % change in area compared to 75 % change in area respectively) 
(Figure 2.1E).  
 
SELENOK-truncated melanoma cells exhibit lower cytosolic Ca2+ levels 
 
The reduced migration and proliferation resulting from SELENOK truncation shown above may 
be due to reduced Ca2+ signaling caused by a decrease in IP3R expression, similar to what has 
been observed in SELENOK deficient immune cells [37]. To determine if SELENOK truncation 
affects intracellular [Ca2+], ester caged IP3 was loaded into unedited or SELENOK-truncated 
clone 7 cells, and uv light was used to uncage the IP3 to induce Ca2+ movement from the ER into 
the cytosol via the IP3R. Compared to unedited controls, SELENOK-truncated clone 7 cells 
demonstrated at least a 3-fold reduction in intracellular [Ca2+] in the cytosol in response to IP3 
engagement of the IP3R (Figure 2.2A). In separate trials, both cell types were treated with 
thapsigargin, which bypasses the IP3R and results in rapid Ca2+ efflux from the ER. Intracellular 
[Ca2+] was similar in response to thapsigargin treatment for both clone 7 cells and unedited cells 
(figure 2.2B), suggesting that reduced intracellular [Ca2+] in clone 7 cells is specific to IP3R 
deficiency. Peak intracellular [Ca2+] from repeat experiments are shown in Figure 2.2C-D. 
Control experiments were performed in order to test if the difference in intracellular [Ca2+] 




The results indicated that SELENOK-truncated clone 7 cells demonstrated at least 2-fold lower 
intracellular [Ca2+] at all IP3 concentrations tested compared to unedited cells (Figure S2.3A-B). 
A small increase in intracellular [Ca2+] was observed when the cells were exposed to uv pulse 
alone (no IP3 loaded), however, no difference between unedited and clone 7 cells was observed 
(Figure S2.3C).   
 
Calcineurin activity and NFAT nuclear localization are reduced in SELENOK- truncated 
melanoma cells.  
 
Modulation of Ca2+ levels in the cytoplasm can affect a wide variety of Ca2+ dependent cell 
signaling systems including calcineurin signaling [144]. Dysregulation of calcineurin activity has 
been observed in many cancers [149] and is a downstream mediator of the common BRAF 
mutation common in melanomas [150]. Therefore, the enzymatic activity of the phosphatase 
calcineurin was measured in unedited and clone 7 cells. Calcineurin activity in SELENOK-
truncated clone 7 cells was lower compared to unedited cells (Figure 2.3A). The calcineurin 
inhibitor Cyclosporin A (CsA), lowered unedited cell calcineurin activity levels to 0.0035 nmol 
phosphate/min, equivalent to the rate exhibited in clone 7 cells, but did not affect calcineurin 
activity in clone 7 cells. Importantly, differences in phosphatase activity between unedited and 
clone 7 cells were not due to the activity of PP1 or PP2A phosphatases (Figure S2.4A) or 
differences in levels of calcineurin subunits A and B or calmodulin (Figure S2.5).  
 
When calcineurin is activated it cleaves multiple phosphate groups from NFAT and induces its 
translocation to the nucleus [146]. Therefore, to test if SELENOK-truncation affects NFAT 
translocation to the nucleus, recombinant GFP-NFAT was transfected into unedited and clone 7 
cells and translocation was visualized using confocal microscopy. Higher levels of NFAT in the 
cytosol of clone 7 cells compared to unedited cells was observed (Figure 2.3B), which is 
consistent with lower levels of endogenous calcineurin activity in SELENOK-truncated clone 7 
cells. Taken together, these results suggest that reduced Ca2+ flux due to the absence of 




activity and thus decreased translocation of the transcription factor NFAT to the nucleus, which 
may result in impaired downstream programs such as growth, proliferation, and migration.  
 
SELENOK deficiency alters transcriptional control of metabolism and migration and 
stemness 
 
Because the calmodulin-calcineurin-NFAT signaling axis was altered in SELENOK-truncated 
clone 7 cells compared to unedited cells, SELENOK truncation may lead to altered gene 
transcription. Gene array experiments were conducted that led to the identification of 166 up-
regulated and 113 downregulated transcripts by greater than 2-fold in clone 7 cells compared to 
unedited control under basal conditions. The full list of transcripts up- or down- regulated by 
greater than 2-fold is shown below (Figure S2.6) and a heat map was generated that includes 
genes related to cancer growth, metabolism, metastasis, and stemness (Figure 2.4A). Transcripts 
decreased by SELENOK-truncation included some involved in promoting growth and 
metabolism (e.g. XYLT1 and ACSM3), invasion and metastasis (e.g. MMP1 and TRPV4), and 
stemness (e.g. Prom1). Furthermore, SELENOK-truncation increased level of transcripts 
involved in promoting cell attachment (e.g. ITGA2 and ITGB5).  
 
In order to confirm the gene array results, real-time PCR was performed. The real-time PCR 
results were consistent with the gene array analysis for the genes selected (Figure 2.4B). Next, 
protein levels for ITGA2, ITGB5, and Prom1 were evaluated by western blot and flow 
cytometry. Consistent with the changes in mRNA, protein levels were increased for ITGA2 and 
ITGB5, and decreased for Prom1 in SELENOK-truncated cells (Figure 2.5A-C). Signaling 
pathway analyses revealed how the factors listed above and other signaling nodes that are cancer 
related were affected by SELENOK truncation (Figure S2.7)  Taken together these results 
suggest that SELENOK truncation in melanoma cells lead to reduced IP3R generated Ca2+ flux 
and altered cell programs that resulted in decreased growth and metabolism, an increase in cell 






SELENOK truncation increases adhesion and reduces migration in melanoma cells 
 
The increased protein expression in the integrins ITGA2 and ITGB5 in SELENOK-truncated 
clone 7 cells, although modest, suggested that SELENOK deficiency may alter cell migration 
and attachment. To determine if SELENOK deficiency impairs migration rates of melanoma 
cells, an electrode/resistance assay was performed using unedited and SELENOK-truncated 
clone 7 cells. The rate of migration of both cell types was estimated by the resulting resistance, 
measured in µm/h, caused by cellular movement into the “wound”. Unedited cell movement into 
the cleared area was approximated to be 300 µm/h while clone 7 cell movement was estimated to 
be approximately 150 µm/h. (Figure 2.6A). Extracellular matrix (ECM) proteins play an integral 
role in the initial steps of migration and invasion during metastasis [171], so adherence and 
transwell assays using collagen I or fibronectin matrices were performed. SELENOK-truncated 
clone 7 cells showed relative lower transwell migration and relative higher adherence in the 
presence of both collagen I and fibronectin compared to unedited cells (Figure 2.6B-C). These 
results suggest that deficiency in functional SELENOK in melanoma cells increases adhesion to 
ubiquitous components of the ECM while reducing their ability to migrate. 
 
In vivo SELENOK-deficiency reduces melanoma progression and metastasis 
 
To determine the role of SELENOK in melanoma progression in vivo, we utilized a spontaneous 
melanoma transgenic (Tg) mouse model that overexpresses glutamate receptor 1 (Grm1) under 
the control of the melanocyte specific tyrosine-related protein 2 (Trp2) promoter [142, 172]. This 
mouse model is characterized by the development of melanoma on the ears, tails, perianal 
region, and metastases to the draining lymph nodes, liver and lung between 2-4 months of age 
with 100% penetrance. Using these mice, a breeding scheme was developed to delete the 
SELENOK gene on the Grm1-Tg background. This breeding scheme resulted in littermates 
having three different genotypes: Grm1/SELENOK+/+, Grm1/SELENOK+/-, and 
Grm1/SELENOK-/-. The littermates grouped by different SELENOK expression levels (normal 
vs. deletion) were used to evaluate the progression of primary and secondary tumors under 




groups were analyzed separately for tumors on the tails and ears at 4 months of age. Gross 
anatomical evaluation of littermates demonstrated that Grm1-Tg mice with both alleles of 
SELENOK knocked out exhibited lower levels of primary tumors and less metastases to the 
draining lymph nodes (Figure 2.7). The Grm1-Tg mice with either one or two alleles of 
SELENOK developed intermediate to severe melanoma on the tails and ears and metastases to 
the draining lymph nodes, observable as pigmented cells in the inguinal and auxiliary lymph 
nodes. The results were similar for males and females, suggesting no sex differences in terms of 
SELENOK deficiency on melanoma in this model. The melanoma in the Grm1-Tg mouse model 
is not lethal [142], therefore, survival analyses was not performed. However, the mice in the 
littermates were followed up to 8 months of age and the Grm1/SELENOK-/- mice continued to 
exhibit a lesser burden of primary and secondary tumor formation compared to 
Grm1/SELENOK+/+ and Grm1/SELENOK+/- littermates for both sexes (Video 1).  
 
To confirm deletion of SELENOK in Grm1/SELENOK-/- mice and the consequent reduction of 
IP3R expression as observed SELENOK-truncated SK-MEL28 cells, western blot was 
performed. As expected, the littermates with complete deletion of SELENOK exhibited 
relatively lower levels of IP3R compared to Grm1/SELENOK+/+ and Grm1/SELENOK+/- 
littermates in splenocytes (Figure 2.8A). To quantify tumor expression in the tails and ears of the 
littermates, a microscopy approach was used involving color threshold analyses of melanin 
levels in tail and ear tissue cross-sections. The three littermate genotypes, Grm1/SELENOK+/+, 
Grm1/SELENOK+/-, and Grm1/SELENOK-/- were analyzed for both male and female mice at 4 
months of age (N = 7 per sex per genotype). In addition, two control groups not expected to 
develop tumors due to absence of the Grm1 transgene were also analyzed: C57BL/6J and 
SELENOK-/- mice (N = 7 per sex per genotype). Analyses of pigmented areas, likely due to 
melanin producing melanoma cells, demonstrated that Grm1/SELENOK+/+ and 
Grm1/SELENOK+/- mice expressed pigmented tissue 60-70% relative to normal tissue. 
However, Grm1/SELENOK-/- mice expressed only 30% pigmented tissue compared to normal 
tissue, which is comparable to both control groups (Figure 2.8B-C). The results were similar for 
both male and female cohorts in both tissues examined. Next, cells were dissociated from the 




cells expressing the Prom1 cancer stem cell marker [173]. Results indicated that and 
Grm1/SELENOK+/+ and Grm1/SELENOK+/- mice exhibited approximately 40% Prom1+ cells 
compared to approximately 25% Prom1+ cells in Grm1/SELENOK-/- mice and controls (Figure 
2.8D), which is consistent with the cell line data above showing that SELENOK deficiency 
decreases cellular markers of stemness.  
 
Finally, to evaluate metastasis in the different Grm1/SELENOK littermate expression controlled 
groups and the non-tumor forming control groups, the draining lymph nodes (inguinal and 
axillary) were evaluated utilizing two approaches. First, light microscopy was used to evaluate 
the amount of melanin producing, infiltrating cells in the lymph nodes for qualitative assessment 
(Figure 2.9A). Second, immunofluorescent detection of the melanocyte specific marker, Trp2, 
was quantified (Figure 2.9B-C). The latter was included because melanoma cells that have 
metastasized to secondary tissue in this model may lose the ability to express melanin [172]. 
Specificity of this immunofluorescent approach was confirmed (Figure S2.8). Both approaches 
showed reduced melanoma expression in the lymph nodes of the Grm1/SELENOK-/- mice 
compared to Grm1/SELENOK+/+ and Grm1/SELENOK+/- mice, which had similar levels of 
melanoma in their lymph nodes. Overall, these data suggest that SELENOK expression is 
required for the progression of primary melanoma tumors as well as metastasis to the draining 

















Thus far, a role for SELENOK in cancer progression has not been described. The data presented 
here suggest that SELENOK acts to promote melanoma tumor progression and metastasis to 
distant sites. Mechanistically, the data suggest that SELENOK promotes the progression of 
metastatic melanoma by ensuring the palmitoylation and thus stable expression of the IP3R in 
the ER membrane, which is required for efficient Ca2+ flux. High intracellular [Ca2+] is required 
for induction of downstream Ca2+ calcium dependent signaling pathways that turn on cellular 
programs related to growth, migration, and proliferation. Numerous studies have demonstrated a 
strong correlation between SELENOK and maintenance of IP3R-dependent Ca2+ flux in a variety 
of immune cells [37, 174]. The data presented here suggest a role in promoting IP3R-dependent 
Ca2+ flux-dependent functions such a growth, stemness, proliferation, and invasion in cancer 
cells both in vitro and in vivo.  
 
The importance of SOCE in regulating melanoma and proliferation and cell migration was 
previously suggested by experiments including a knockdown of STIM1 or Orai1 in human 
melanoma cell lines and a pharmacological inhibitor of SOCE [107]. Similar results were found 
for knockdown of STIM1 and Orai1 in breast tumor cells [106] and in glioblastoma tumor cells 
[100]. The gene array data suggest that growing melanoma cells require SELENOK for initiating 
transcriptional programs related to their metabolism, stemness, and invasive properties. 
However, further experiments need to be performed in order to conclude that induction of these 
cellular programs rely solely on SOCE. Interestingly, Stim and Orai1 transcripts were not 
affected by SELENOK expression in melanoma cells. Several experiments were attempted to 
clarify if Ca2+/calmodulin-dependent calcineurin activity directly modulated the transcripts levels 
observed by SELENOK deficiency. Using CsA or FK506 inhibitors on unedited and clone 7 
cells followed by real-time PCR measuring levels of the mRNA transcripts in question, we were 
not able to generate consistent results. This may have been due to technical issues or the non-
synchronized nature of the growing cells that led to the inconclusive results. Therefore, the 
results support a role for SELENOK in regulation of transcriptional programs supporting 




changes are due to effects of SELENOK on cytosolic Ca2+ levels that then subsequently induce 
the changes in gene expression. It is worth noting that a lower activity of calcineurin caused by 
SELENOK deficiency leading to lower NFAT nuclear localization could reduce levels of some 
of the transcripts observed, but it is less intuitive how that may lead to higher transcript levels 
observed for other genes. Increases in mRNA for select genes could be due to secondary effects 
arising from lower NFAT translocation such as compensation from other transcription factors, 
but more experiments are required to confirm this.  
 
Metastasis is a stepwise process that involves loss of adhesion from the primary tumor, migration 
through the ECM and extravasation through the basement membrane, and adhesion and survival 
at a distal site. All the steps listed for metastasis rely on tightly regulated Ca2+ flux [175], and the 
results provided above suggest that loss of SELENOK in SK-MEL28 cells leads to increased 
adhesion and decreased migration/metastasis. One intact allele of SELENOK was sufficient for 
in vitro melanoma cell function and in vivo tumor progression. This suggests that high level of 
SELENOK protein is not necessarily required for malignant melanoma progression, which is 
consistent with the human tissue and NCI-60 melanoma cell lines data showing that SELENOK 
protein levels are not increased in melanoma compared to normal cells or tissues. Furthermore, 
the CRISPR/Cas9 version of SK-MEL28 with one truncated allele of SELENOK, and cells 
derived from the Grm1-Tg/SELENOK+/- mice indicate that SELENOK expression levels are 
normally well above what is necessary and sufficient. That is, SELENOK is not limiting and as 
such, further increases in SELENOK expression would bot be expected to have additional 
effects. 
 
Changes in the expression of STIM1 and Orai1 have been found in a many cancer types, 
including melanoma [176], and thus have been implicated cancer progression. However, some 
reports have shown no differences in STIM1 or Orai1 levels in non-malignant vs. malignant cells 
[177]. Indeed, there remains heterogeneity in the levels of these and other SOCE components 
(e.g. IP3Rs) in melanoma [170]. Since SELENOK is a cofactor that binds to the DHHC6 enzyme 
to catalyze the palmitoylation of the IP3R required for its stability in the ER membrane, it could 




lead to more IP3R expression in the ER membrane. However, genetic engineering of the 
SELENOK gene in vitro and in vivo that led to significantly lower levels of full-length protein 
plainly reduced SOCE in melanoma cells. This suggests that a threshold of SELENOK protein 
levels exists that is necessary for efficient Ca2+ flux in melanoma cells, resembling what has been 
observed in immune cells, but that threshold is well below normal expression levels.  
 
Targeting components of SOCE or Ca2+ signaling as a therapy for cancer is an emerging area of 
interest in cancer research [82]. Orai and STIM proteins appear to be attractive molecular targets 
for cancer therapeutics [178]. However, Ca2+ flux is ubiquitous and plays a critical role in normal 
cells for proliferation, survival, metabolism, differentiation, etc., [179]. Furthermore, specific 
calcium pathways have also been identified as integral in the establishment and maintenance of 
multidrug resistance and the tumor microenvironment [180]. Homozygous mutations or 
disruption of both alleles of STIM1 or Orai1 results in perinatal lethality and STIM-2 knockout 
mice only survive ~5 wks of age [181-184]. The observation that SELENOK knockout mice 
show very little phenotypic defects and their fertility is not affected, suggests that therapeutic 
targeting of SELENOK may produce far fewer side effects. While CsA has been shown to be an 
effective treatment for melanoma in vitro [185], its use may negatively affect healthy cells that 
rely on NFAT for their normal growth and proliferation. The possibility of reduced side effects, 
along with the impressive reduction of melanoma with SELENOK deficiency in a mouse model 
of melanoma presented herein, support further investigation of SELENOK as a treatment of 
melanoma or other metastatic cancers that hijack SOCE. Genetic ablation of the gene encoding 
SELENOK eliminates its protein expression throughout development, which is not equivalent to 
using inhibitor drugs to inhibit its function. Therefore, future studies involving inducible 
knockdown of SELENOK, that would better reflect therapeutic intervention are planned. Finally, 
previous work in the Hoffmann laboratory identified the functional domain of SELENOK for its 
cofactor activity for DHHC6, which consists of amino acids 82-94 [10, 71], which helped guide 
the development of peptide inhibitors described in chapter 3. Overall, the in vitro and in vivo data 
regarding SELENOK deficiency and melanoma support further investigation into this protein as 









Generation of SELENOK-/- have been previously described [37] and C5BL/6J obtained from 
Jackson Laboratories were used as controls. Grm1-transgenic (Tg) mice [142, 172] were 
obtained from Dr. Suzie Chen at Rutgers University and used to establish a transgenic colony. 
The SELENOK-/- mice were crossed with the Grm1-Tg mice and the F1 generations crossed with 
each other to generate littermates with the following phenotypes: Grm1-Tg/SELENOK+/+, Grm1-
Tg/ SELENOK+/-, and Grm1/ SELENOK-/-. All animal protocols were approved by the 
University of Hawaii Institutional Animal Care and Use Committee.  
 
Cells, antibodies, and reagents 
 
Lysates from primary melanocytes were purchased from ScienCell Research Laboratories 
(Carlsbad, CA) and NCI-60 validated human melanoma cell lines obtained from the University 
of Hawaii Cancer Center included SK-MEL2, SK-MEL28, and MALME-3M. These cell lines 
were cultured in RPMI media with 10% fetal bovine serum and 1% Antibiotic-Antimycotic (all 
from GIBCO/ThermoFisher). Primary antibodies for western blots included rabbit monoclonal 
anti-SELENOK (Epigemonics, Inc., custom antibody), anti-IP3R1 (Santa Cruz Biotechnology) 
(fology, sc-271197), anti-GAPDH (Santa Cruz Biotechnology, sc-47724), anti-Prom1 (Cell 
Signaling, 58605). Antibodies from Abcam included anti-Trp2 (ab74073), anti-calcineurin A and 
B (ab137335, ab154650 respectively), and anti-calmodulin (ab 105498). Western blot secondary 
antibodies were purchased from Li-Cor Technologies and immunofluorescence secondary 











For measurements of proliferation, cells were grown to 90% confluency in flasks and then 
trypsinized, resuspended and plated at 1000 cells per well in 4 separate black 96-well plates. On 
days 1, 2, 3, and 4 one plate was removed from incubation and centrifuged at 400 RCF for 4 min 
to pellet cells. Subsequently, media was removed, and plates were wrapped in parafilm and 
stored at -80° C. On day 5, pellets were thawed and lysed, and cells were quantified using a 
CyQUANT® Kit (ThermoFisher, Inc.). A fluorescence plate reader (Molecular Devices, Inc.) 
was used to quantify fluorescence of samples and cell count was inferred from a previously 
recorded standard curve using SK-MEL28 cells. 
 
Scratch assays were performed by first growing cells to 90% confluency in a six-well plate. A 
“wound” is created in the center of each well by dragging a p-200 pipette tip through the cells at 
day 0 and pictures were taken using an Olympus 1X71 inverted microscope and Picture Frame 
software. After 18 h a secondary set of pictures were taken, and ImageJ was used to measure the 
area of the “wound” on day 0 and day 1. Results represent the change in area of the “wound” 




Cellular migration rates were measured using transwell assays as previously described 
(Sulzmaier 2016). The lower sides of transwell filters (8 µm pore size; Greiner Bio-One) were 
coated with 15 µg/ml human plasma fibronectin (Life Technologies) or collagen I overnight at 
4C. Cells (1 × 106) were plated on the top-side of the filters in serum free media, with the 
bottom chambers containing incomplete media supplemented with 10 ng/ml EGF. Cells were 
incubated for 20 hours at 37 C; 5% CO2. The number of cells that migrated through the 
membrane was measured through Calcein-AM dye (Sigma-Aldrich) uptake and fluorescence at 
495 nm excitation/515 nm emission.  
The wound healing assay was performed on an 1600R ECIS instrument (Applied Biophysisc, 




trypsin/EDTA), washed and seeded in fresh media onto ECIS 8W10E+ PET slides at a 
concentration of 2.5 × 105 cells/mL. The rate of migration was measured as a function of time 
needed to climb back up to base resistance levels. Migration rate = electrode radius (µm)/ ∂time 
(h); ∂time = t2–t1 where t2 = time point in hours when resistance reading reaches base reading, 




The cell attachment assay has been previously described [187]. Briefly, microtiter plates coated 
overnight at 4C with human plasma fibronectin (Millipore) or collagen I (Upstate NY) at 10 
g/ml were blocked with 3% BSA for 1 h at 37C, wells were rinsed once with PBS (pH 7.4) 
and cells were added (1 × 105 cells/ml) in serum free media. Cells were incubated for 60 min at 
37C; 5% CO2. After 60 min plates were washed 1X with PBS, fixed with 3% 
paraformaldehyde, stained with 0.5% crystal violet, 20% MEOH, washed under running distilled 
water, solubilized in 0.5% Triton X-100 in distilled water overnight R.T. and read on an ELISA 
plate reader at 595 nm. 
 
Flow cytometry  
 
Flow cytometry was performed using 5 × 105 cells by incubating with phycoerythrin (PE)-
conjugated isotype control IgG or PE-conjugated IgG specific for Prom1 or ITGA2 or ITGB5 
(all from BioLegend) and used 5 µL antibody per test as recommended by the vendor. Dead cells 
were excluded from analyses using violet blue exclusion dye (BioLegend). Samples were 
analyzed using the Attune NxT flow cytometer (ThermoFisher) and FlowJo software. Epidermal 
cells were disassociated from mouse tails by first separating the epidermis from the dermis using 
an Epidermis Dissociation Kit (Miltenyi) and generating a single cell suspension using 
GentleMacs. Cells were incubated with Fc-block followed by APC-anti-Prom1 (both Biolegend 
per vendor’s instructions). Cells were then fixed using 2% paraformaldehyde and analyzed on a 







Cells were lysed in buffer containing 150 mM NaCl, 50 mM Tris, 1% Triton X-100, 1% sodium 
deoxycholate, and protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA) at 
4°C for 1 h. Insoluble material was removed by centrifugation at 20,000 RCF for 10 min, and 
total protein in the supernatant was determined using a Bradford assay reagent (Bio-Rad, 
Hercules, CA, USA). After adjusting to equal protein concentration, cell lysates were boiled in 
SDS sample buffer and then separated by SDS-PAGE, followed by transfer of the proteins onto 
nitrocellulose membranes. Blots were incubated with the one or more of the primary antibodies 
listed in cells, antibodies, and reagents, for 1.5 h, washed, incubated with secondary 
Alexafluor595 antibody (ThermoFisher), and visualized using the Odyssey Scanner (Li-Cor). 
 
Genome editing and transfections  
 
A CRSPR/Cas9 approach was used to mutate the SELENOK gene (NCBI geneID 58515), in SK-
MEL28 cells, in order to generate a cell line expressing a truncated, nonfunctional SELENOK 
protein. First, SK-MEL28 cells were transfected with a pSpCase9(BB)-2A-GFP (Addgene) using 
Lipofectamine 2000 (ThermoFisher). After 24 h, FP-positive cells were sorted using a FACSaria 
(BD Bioscience) into RPMI 1640 medium with 20% FBS without antibiotics. These cells were 
then transfected with Integrated DNA Technologies (IDT) guide RNA/transactivating RNA 
complexes in IDT complex buffer for 30 min using Lipofectamine 2000. Cells were recovered in 
RPMI 1640 medium with 20% FBS without antibiotics for 24 h, then 7-AAD Viability Stain 
Solution (Biolegend, Inc.) was added and a final round of cell sorting carried out using the 
FACSaria instrument. The GFP+AAD- cells were sorted into 96-well plates with one cell per well 
in 200 µL of RPMI 1640 media with 20% FBS and no antibiotics. After ~3 weeks, live clones 
were transferred to 24 well plates and further grown expanded. Colonies were screened by 







Intracellular Ca2+ measurement 
 
For time-lapse video microscopy, cells on coverslips were loaded with FuraRed (Enzo Life 
Sciences) with either 1.00 µg/mL, 0.500 µg/mL, 0.250 µg/mL, or 0.00 µg/mL caged IP3 (D-23-
O-Isopropylidene-6-O-(2-nitro-4.5-dimethoxy)benzylmyo-inositol 1,4,5-trisphosphate-
Hexakis(propionoxymethyl) ester) (Enzo Life Sciences) for 30 min at 37° C followed by a 1 h 
recovery. The coverslips were then mounted onto RC-25F chambers (Warner) and placed into 
the mount of a Zeiss Pascal inverted confocal microscope with LSM5 dual lasers and camera. 
The fluorescence intensity of the FuraRed was measured at 2 sec intervals for 1 min and then 
cells exposed to uv light for 2 sec to uncage the IP3 molecule and fluorescence measurements 
continued for 3 min. Thapsigargin was used as a control as previously described [37]. The ratio 
of red fluorescence was inverted to represent increased Ca2+ since FuraRed signal decreases 
with increased cytosolic Ca2+ and results expressed as F1/F0. 
 
Calcineurin activity assays and NFAT localization 
 
Phosphatase activity was measured from lysates prepared from SK-MEL28 unedited and clone 7 
cells using the calcineurin cellular activity assay kit (Enzo). Cells were treated with either 2 µM 
cyclosporin A (Sigma) in DMSO or DMSO as vehicle control for 2 h. Cells were lysed as per the 
vendors instructions and lysates were normalized to equal total protein concentration as 
determined by Bradford assay. Phosphatase activity was measured from cellular protein extracts 
as the dephosphorylation rate of calcineurin specific phosphopeptide substrate (R-II 
phosphopeptide) in the presence of 0.5 mM CaCl2/0.25 μM calmodulin. The malachite green 
based colorimetric assay was measured on a SpectraMax 384 microplate reader (Molecular 
Devices Inc.). NFAT localization was assessed by transfecting cells with a plasmid encoding 
GFP-c1NFAT3 (Addgene) using Lipofectamine 2000 (Invitrogen) with or without 2 µM 
cyclosporin A (Sigma) for 18 h. Immunofluorescence microscopy was carried out with a Leica 








SK-MEL-28 unedited and Clone 7 cells were harvested at 80% confluency were plated in 6-well 
plates (6 × 105 cells per well) and grown for 48 h followed by RNA isolation using the EZNA 
Total RNA kit (Omega Biotek, Inc). RNA integrity was validated on Agilent 2100 Bioanalyzer 
using RNA Nano chip. For gene expression profiling, 100 ng of total RNA was used for 
downstream processing using GeneChip Whole Transcript Expression protocol followed by 
hybridization to Clariom S, Human Arrays (Affymetrix, Santa Clara, CA, USA). Subsequently, 
arrays were washed, stained and scanned using GeneChip Fluidics Station 450 and GeneChip 
Scanner (Affymetrix). Generated CEL files were normalized using the SSTRMA-GENE-FULL 
algorithm in the Affymetrix GeneChip Expression console software. Raw CEL files generated 
from Clarion S human microarray were preprocessed in Array Studio (version 9; OmicSoft, 
Cary, NC) using data normalization by the Robust Multi-array Average (RMA) approach. Genes 
with Exp2 (default) transformed fold change greater or less than 2 and Benjamine & Hochberg 
FDR-adjusted p-value < 0.05 were considered as differentially expressed in clone 7 cells with 
respect to unedited cells. 
 
Histological and immunofluorescent analyses of tissues 
 
Tails and ears from 4-month of age mice were excised in an equivalent manner from each mouse 
and weighed. To ensure the same areas of tails were analyzed for presence of tumors for each 
mouse, a cross-section was excised 20 mm from the base that was further cross-sectioned into 4 
pieces 1mm in length. The cross-sectioned tails were mounted in the same orientation in tissue 
paper and incubated 10% buffered formalin for 1 wk fix samples. Ears were immediacy 
incubated with 10% buffered formalin for 1 wk for fixation. Both fixed tails and ears were then 
incubated in 10% EDTA (w/v) for 1 wk to remove cartilage. The tail and ear samples were 
dehydrated in a series of ethanol solutions and embedded in paraffin, sectioned, and stained 
using a Leica CM1900 UV cryosectioner, Leica EG1160 and Microm HM340E microtomes, and 
a Leica automated tissue processor followed by standard Hemotoxylin and Eosin (H&E) staining 




and immunofluorescent staining. Processing for H&E staining followed the protocol described 
above except the lymph nodes were fixed with 10% buffered formalin for 1 d and were not 
incubated with EDTA. For immunofluorescent staining, sectioned samples on glass slides were 
dried overnight in 45-50 ºC overnight, deparaffinized, and rehydrated under high temperature 
and pressure in Trilogy™ (Millipore Sigma) to unmask antigens. ImmEdge pen was used to 
create a hydrophobic border around the tissue and 5% goat serum (Vectastain) was added for 1 h 
to block non-specific binding. Primary antibody (rabbit anti-Trp2; Abcam, Inc.) was added at a 
final concentration of 1:500 in 5% goat serum in PBS for 2 h at RT. After three washes with 
PBS, secondary antibody (rabbit Alexafluor594; ThermoFisher) was added at a final 
concentration of 1:1000 in 5% goat serum in PBS for 1h at RT. After three washes with PBS, 
tissues were mounted in vectashield H-1200 with DAPI (Vector Labs, Inc.). 
 
The H&E stained sections were imaged using a Zeiss Axioskop 2 Plus upright light microscope 
with camera and AxioVs40 V 4.7.2.0 acquisition software, equipped with a 5X Plan neofluor 
objective, 5X/.15, α/.17 numerical aperture of 0.9. Light microscope images were analyzed using 
ImageJ software. The amount of tumor tissue present in ears and tails were determined by setting 
the signal intensity representing dark melanin at threshold and then measuring the total surface 
area of tissue along with the surface area above the threshold. The percentage of melanin tissue 
above color threshold per total surface area was calculated. The lymph nodes were analyzed by 
immunofluorescence using a Leica Microsytems LAS AF TCS SP5 confocal microscope with a 
40x oil objective with 5x zoom, HCX PL APO CS with numerical aperture of 1.3. The Laser 
lines used were 405 nm (for DAPI) and 594 nm (for Alexafluor594). Images were captured using 
LAS AF version 2.7.3.9723 acquisition software, 1997–2012 LeicaMicrosystems CMS GmbH. 
A minimum of 4 fields per sample was captured and ImageJ was used to analyze tissue for Trp2 
signal with data presented as mean fluorescence intensity. 
 
Statistical analyses  
 
Comparison of two means was carried out using an unpaired Student’s t test using GraphPad 




analyze groups with Tukey post-test used to compare means of each group. All comparisons 
were considered significant at p < 0.05. GraphPad Prism was also used to generate standard 


































Figure 2.1: Loss of Functional SELENOK in melanoma cells leads to decreased 
proliferation. (A) Western blot analysis demonstrating similar SELENOK levels in primary 
human melanocytes and three human melanoma cell lines. GAPDH was used as a loading 
control. (B) Diagram illustrating how CRISPR/Cas9 was used to edit the genome of SK-MEL28 
cells, generating a truncated version of SELENOK that has the functional domain deleted. (C) 
Western blot analysis confirmed the presence of full-length SELENOK in unedited cells, both 
full-length and truncated in clone 3 cells, and only truncated SELENOK in clone 7 cells. Only 
clone 7 exhibited reduced IP3R levels. GAPDH was used as a loading control. (D) Equal 
numbers of cells were plated in replicate well (N = 6 per cell line) and proliferation was 




expressed as mean ± SEM and a one-way ANOVA with Tukey post-test was used to analyze the 
groups. Means at each time point without a common letter differ, p < 0.05. (E) Wound healing 
assays were performed in triplicate comparing unedited SK-MEL28 cells to clone 3 and clone 7 
cells. Results showed less cellular closure of the scratched region for clone 7 cells. Results are 
expressed as mean ± SEM and a one-way ANOVA with Tukey post-test was used to analyze the 
groups. Means at each time point without a common letter differ, p < 0.05. For D-E, results were 




Figure 2.2: IP3R-dependent cytosolic Ca2+ concentration is reduced in SELENOK-
truncated melanoma cells. (A) SK-MEL28 unedited and clone 7 cells were loaded with both 
caged IP3 (0.50 µg/mL) and the Ca2+ sensitive fluorochrome, FuraRed. Confocal microscopy 
was used to measure baseline fluorescence for 30 sec, followed by exposure to a 2 sec uv light 




within the cells. Because FuraRed fluorescence decreases upon Ca2+ in the system used, the 
fluorescence intensity was inverted and plotted as signal after uncaging of IP3 (F1) divided by 
the average baseline signal (F0). Results showed reduced Ca2+ flux in clone 7 cells. (B) 
Thapsigargin, which bypasses the IP3 receptor to induce Ca2+ flux, was used to compare 
unedited SK-MEL28 and clone 7 non-IP3 induced Ca2+ flux. No differences in Ca2+ flux was 
found. Results for A-B Ca2+ flux experiments represent three independent repeats that each 
included ≥ 30 cells per condition. (C-D) IP3 mediated and thapsigargin based experiments were 
independently repeated in triplicate, means of the replicates were compared using a student’s t-
test and expressed as mean ±SEM with *p < 0.05.  
 
 
Figure 2.3: Calcineurin activity and NFAT nuclear localization are reduced in SELENOK-
truncated melanoma cells. (A) SK-MEL28 w.t and clone 7 cells were incubated for 2 h with 
DMSO vehicle control or the calcineurin inhibitor, cyclosporin A (CsA) (2 µM), and then cell 




added to lysates and colorimetry was used to detect production of phosphate. Means of replicates 
(N = 3) were compared using a student’s t-test and expressed as mean ± SEM with * p < 0.05. 
All experiments are representative of a minimum of two independent experiments. (B) GFP-
NFAT was transfected into SK-MEL28 unedited and clone 7 cells and using the same CsA 
conditions as in A, GFP-NFAT localization was evaluated using confocal microscopy. Results 
showed that SELENOK-truncated clone 7 cells had accumulation of NFAT in the cytosol 
(identified morphologically) in a manner similar to cells treated with CsA. DAPI staining of the 
nuclei was recolored from blue to red to allow merged (yellow) to be more apparent. Scalebar 




Figure 2.4: SELENOK deficiency alters transcriptional control of growth, migration and 
stemness. (A) Gene arrays were used to compare SELENOK-truncated clone 7 cells to unedited 




cancer progression and growth were selected based on Exp2 (Array Studio default) transformed 
> 2-fold higher or lower than unedited control cells with Benjamini & Hochberg FDR-adjusted 
p-value < 0.05. A heat map was generated using the linear gene expression values, which were 
normalized by dividing the unedited average and robust center scaling with a linear range of 1 to 
-1. Down-regulated (green) and up-regulated (red) genes are shown for clone 7 compared to 
unedited cells or vice versa. Arrows indicate genes that were further examined. (B) Real-time 
PCR was used to measure relative mRNA levels for selected genes. Results confirmed that clone 
7 cells demonstrate down regulation of the five transcripts involved in promoting growth, 
stemness, and migration (upper graph) and up-regulation of 2 transcripts involved in adhesion 
(lower graph). Means of replicates (N = 4) were compared using a student’s t-test and expressed 




Figure 2.5: Protein levels for Prom1 as well as ITGA2 and ITGB5 integrin chains are 
altered in a manner similar to transcript levels with SELENOK deficiency. (A) Flow 
cytometry was used to evaluate surface expression of Prom1, ITGA2 (α2), and ITGB5 (β5). PE-
labeled isotype control antibodies did not bind either wild-type (WT) cells or clone 7 cells (two 




intensity for ITGA2 (α2) and ITGB5 (β5) integrin chains. (B) The fluorescence intensity was 
measured for replicates (N = 3) and means were compared using a student’s t-test and expressed 
as mean ± SEM * p < 0.05. (C) Prom1 protein levels were also measured using western blot with 
GAPDH used as a loading control.  
 
Figure 
2.6: SELENOK deficiency alters adhesion and migration of melanoma cells. (A) Migration 
rates were measured for unedited SK-MEL28 cells and SELENOK-truncated clone 7 cells using 
electrode-created wounds and resistance to measure movement of cells into electrode cleared 
area. (B) Adherence to fibronectin and collagen I was measured for unedited SK-MEL28 cells 
and SELENOK-truncated clone 7. Clone 7 cells were found to exhibit increased adherence to 
both types of fibers compared to unedited cells. Crystal violet stained cells were measured using 
absorbance read on an ELISA plate reader at 595 nm. (C) Transwell assays were performed to 
test unedited and clone 7 cells for migration through fibronectin or collagen I. Migration through 
both matrices was lower for clone 7 compared to unedited cells as measured by fluorescent 
stating of the cells. Results represent three independent experiments. Means of replicates, N = 3 
for A and N = 6 for C-D, were compared using a student’s t-test and expressed as mean ± SEM * 








Figure 2.7: Deletion of SELENOK in vivo results in reduced primary and secondary 
tumors in Grm1-Tg mice as analyzed by gross anatomy. The Grm1-Tg mouse line 
spontaneously develops tumor on the tails, ears, and perianal region that metastasize to the 
draining lymph nodes by 4 months of age. Mice shown above were bred with SELENOK 
knockout mice to generate littermates: Grm1/SELENOK+/+, Grm1/SELENOK+/-, and 
Grm1/SELENOK-/- mice. (A) Examination of the primary tumors on the ear and tails revealed 
lower primary tumor formation for Grm1/SELENOK-/- mice compared to Grm1/SELENOK+/+ 
and Grm1/SELENOK+/- which both exhibited tumor formation ranging from intermediate to 
high. (B) Evaluation of secondary tumors in the draining lymph nodes showed less secondary 










Figure 2.8: SELENOK deficiency reduces melanoma tumor burden on tails and ears. (A) 
Western blot analysis of splenocytes, which express relatively high levels of SELENOK and 
IP3R, confirm that complete knockout of SELENOK leads to reduced IP3R in 
Grm1/SELENOK–/– mice. (B) Male and female littermates at 4 months of age with genotypes of 
Grm1/SELENOK+/+, Grm1/SELENOK+/–, and Grm1/SELENOK–/– were compared for levels of 
melanin positive tissue relative to total tissue in tails and ears. (C) Cross-sections of tails and 
ears were H&E stained and evaluated using an ImageJ color threshold approach as described in 
the Methods section. The dark melanin area relative to total area of tissue was compared for all 
three littermate genotypes. We also included two control groups expected to form no tumors 
(C57BL/6 and    SELENOK–/–) due to a lack of the Grm1 transgene in melanocytes, which 




Grm1/SELENOK–/– mice had significantly reduced tumor growth in tails and ears, while 
Grm1/SELENOK+/+ and Grm1/SELENOK+/– mice were similar in progression of melanoma. 
Similar results were found with males and females. (D) Cells dissociated from were analyzed by 
flow cytometry for Prom1+ cancer stem cells and lower levels were found in Grm1/SELENOK–/– 
mice compared to Grm1/SELENOK+/+ and Grm1/SELENOK+/– littermates. Both sexes were 
included in each group, with representative images shown on the left and data graphed on the left 
(N = 3). A one-way ANOVA with Tukey post-test was used to analyze groups and means 




Figure 2.9: SELENOK deficiency reduces metastasis of melanoma to lymph nodes. Male 
and female littermates of 4 months of age with genotypes of Grm1/SELENOK+/+, 
Grm1/SELENOK+/–, Grm1/SELENOK–/– and non-tumor control groups consisting of C57BL/6 




and axillary lymph nodes (N = 7 per group). (A) H&E stained lymph node sections were 
examined low magnification (5x) for melanocytes, which appear as dark brown cells. Scalebar = 
20 mm. (B) Immunofluorescence performed at 40x was used to detect the melanocyte specific 
antigen, Trp2 (red), in lymph node sections. DAPI (blue) was used to stain nuclei. Scalebar = 2 
mm. (C) Trp2 fluorescence was quantified using ImageJ with a minimum of 7 mice per group 
and 3 sections analyzed per mouse A one-way ANOVA with Tukey post-test was used to 







Figure S2.1: Results from immunohistochemical (IHC) evaluation of early and late stage 
melanoma tissues obtained from the University of Hawaii Cancer Center (UHCC). IHC was 
performed and scored by the UHCC Pathology core for SELENOK along with two other 
selenoproteins, glutathione peroxidase-1 and -4. Results suggest no changes in SELENOK levels 







Figure S2.2: Sanger sequencing results for edited clones compared to unedited SK-MEL-28 
melanoma cells. CRISPR/Cas9 editing led to introduction of a thymidine nucleotide causing a 
frame shift in DNA. This resulted in altered codons corresponding to amino acids 80–83 








Figure S2.3: SELENOK-truncated cells (clone 7) compared to wild-type SK-MEL-28 cells 




performed as in Figure 2.1A-B but with differing concentrations of IP3 whereby SK-MEL28 w.t 
and clone 7 cells were loaded with (A)1.00 µg/mL, (B) 0.500 µg/mL (C) 0.250 µg/mL, or (D) 
0.00 µg/mL caged IP3. Results show consistent reduced Ca2+ flux for clone 7 compared to 
unedited controls in higher concentrations of IP3 used and no differences in unedited and clone 7 




Figure S2.4: Western blotting was performed to determine levels of calcineurin subunits A 
and B, along with calmodulin in SELENOK-truncated cells (clone 7) compared to wild-
type SK-MEL-28 cells. Results showed no differences. Western blot showing that protein 




cells. SELENOK was detected in clone 7 cells as a smaller truncated form as expected and 






Figure S2.5: Additional controls to confirm equivalent levels of non-calcineurin 
phosphatase activity in unedited and SELENOK-truncated cells (clone 7). SK-MEL28 w.t 
and clone 7 cells were incubated for 2 h with DMSO vehicle control or the calcineurin inhibitor, 
cyclosporin A (CsA) (2 µM) with the following additional controls: Background reading to 
control for background phosphate/interfering substance. Total phosphate activity in extract. 
EGTA buffer, (Ca2+/CaM free) for total activity in the absence of active calcineurin (PP2B). OA 
(okadaic acid), an inhibitor of other common phosphatases (PP1 and PP2A). OA + EGTA for 
total activity in the absence of active PP1, PP2A and calcineurin. Purified calcineurin enzyme 







Figure S2.6: Differentially expressed genes in Clone 7 with respect to unedited cells. SK-
MEL-28 melanoma cells along with fold-change (red = up-regulated; green = down-regulated), 







Figure S2.7: Signaling pathway analyses conducted with QIAGEN’s Ingenuity pathway 
analysis (Ingenuity Systems). Green indicates down-regulated transcripts and red indicates up-






Figure S2.8: Specific immunofluorescence staining using anti-Trp2, scalebar = 20 μm. Blue 
staining are DAPI-positive nuclei and red cytosolic staining is Trp2 antigen.  
 
Supplemental video 1: SELENOK deficient mice maintain low tumor burden up to 8 
months. Video shows mice at 6 months of age that exhibit a lack of melanoma (Grm1-
Tg/SELENOK–/–) or high levels of melanoma (Grm1-Tg/SELENOK-/+). As shown in the video, 
the mice with high tumor burden are not severely affected in terms of movement or healthy 
behavior. Several cohorts of both sexes were followed out to the age of 8 months and no 













Although published data suggests that targeting SELENOK with inhibitors may be an effective 
approach for the treatment of cancers that rely on SOCE for disease progression, this approach 
presents several challenges. Preliminary studies have established that anti-SELENOK antibodies 
targeting the C-terminal portion of SELENOK can interfere with the palmitoylation reaction 
catalyzed by the SELENOK/DHHC6 complex. Thus, antibody-based inhibitors 
(immunotherapeutics) may be an effective therapy to treat melanoma and/or other cancers. 
However, SELENOK is an intracellular protein which renders standard immunotherapies 
unrealistic since targets for these drugs are conventionally extra-cellular proteins. Nevertheless, 
intracellular proteins constitute nearly half of the human proteome and represent a large reservoir 
of potential therapeutic targets [188]. Therefore, in order to effectively target intracellular 
proteins such as SELENOK, alternative approaches or new technologies that permit the entry of 
large, hydrophilic therapeutics across biological membranes must be considered. 
 
Synthesis of small molecules that bind to critical regions of target proteins is a more 
conventional approach for developing inhibitors against intracellular proteins like SELENOK. 
However, this approach also presents challenges, such as a need for precise structural 
information of the target protein. This approach is particular limited by the fact that the exposed, 
cytosolic domain of SELENOK is intrinsically disordered [70], which limits the range and 
efficacy of small molecule inhibitors. Another approach for targeting intracellular proteins 
involves the combination of two emerging technologies: single domain antibodies (sdAbs, a.k.a. 
nanobodies) from camelids [189, 190] and cell penetrating peptides (CPPs) [191-193]. In theory, 
these small versions of Abs (~15 kDa) exhibit the high specificity of conventional Abs while 
demonstrating a greater ability to translocate across the cell membranes. Indeed, studies have 
demonstrated the use of humanized sdAb fused to CPPs to effectively inhibit their intracellular 




inhibited viral replication within cells [194-196]. Small molecule inhibitors often have off target 
effects due to promiscuous protein binding, whereas sdAbs exhibit the septicity of conventional 
Abs and therefore may cause less side effects when applied to human health. However, further 
studies utilizing CPP-sdAbs in human trials need to be performed.  
 
A third possible approach for targeting SELENOK for functional inhibition involves taking 
advantage of the SH3 binding domain (SH3BD) in its cytosolic region. Previous studies have 
demonstrated that the SH3BD in SELENOK binds to the SH3 domain of DHHC6 [10], and this 
interaction is required for the palmitoylating function of the SELENOK/DHHC6 complex. 
Numerous studies have demonstrated the possibility of disrupting protein-protein interactions as 
a potential therapy for cancer [197-199]. Furthermore, specificity and inhibitor binding strength 
can be increased via directed mutagenesis of the sequences flanking the PxxP motif within the 
SH3BD [200]. This chapter will focus on our efforts to design an SH3 based inhibitor of 
SELENOK and its successful inhibition of SELENOK/DHHC6 palmitoylation ability in a cell 




















Cell penetrating peptides  
 
Polypeptides, oligonucleotides, and antibodies are intriguing options for new pharmaceuticals 
that can provide specificity and a inhibit a wider range of drug targets. However, because of their 
low biomembrane permeability, delivering them inside of cells is a challenge that must be 
overcome. Fortunately, investigations into this problem have found that certain peptides can 
penetrate the cell membrane and gain entry into the cell. These so called cell penetrating peptides 
(CPPs) are defined as amphiphilic peptides that contain up to 30 amino acids, which can be 
internalized by cells in an energy independent manner or via receptor mediated endocytosis 
[201]. Thus, attaching CPPs to large or hydrophilic drugs can permit their entry into the cell 
where they can bind their intracellular targets. There exist several classes of CPPs that can be 
broadly categorized as either cationic (e.g. HIV TAT), amphipathic (e.g. Pep-1), and 
hydrophobic             (e.g. HN-1). Several studies have shown the efficacy of CPPs in the delivery 
of cargo to tumor cells [202-204] but more investigation into their efficacy in treating human 
disease is necessary.  
 
Penetratrin is a sequence of 16 amino acids (RQIKIWFQNRRM KWKK), derived from the third 
helix of the Drosophila Antennapedia homeodomain protein and was the first CPP derived from 
non-viral protein [205]. Translocation of penetratin through the cell membrane occurs even when 
bound to relatively large, hydrophilic molecules, including oligonucleotides, peptides, nucleic 
acids etc. For example, penetratin has been shown to be effective in the delivery of siRNA to 
primary mammalian neurons [206] and delivery of peptides containing cytotoxic T lymphocyte 
(CTL) epitopes to target cells [207]. In our efforts to generate an inhibitor against SELENOK, 
we have included the penetratin sequence proximal to the N-terminus of the peptide inhibitor, 






Intrinsically disordered proteins  
 
The protein structure-function paradigm, which states that a well-defined structure is necessary 
for protein function, dominated the scientific communities’ understanding of protein function in 
the 20th century. Only recently, an appreciation for the number and importance of disordered 
proteins has developed. Indeed, it was only at the end of the 20th century when it was formally 
proposed that naturally flexible proteins are not just rare exceptions, but instead represent a 
unique and broad class of proteins [208-210]. The generally accepted definition of intrinsically 
disordered protein (IDP) is a protein, (or protein domain) that is biologically active, but exists as 
collapsed or dynamically mobile at either the level of secondary or tertiary structure [211]. IDPs 
are associated with a large variety of biological functions, including cell signaling, scaffolding, 
and recognition of misfolded proteins [212]. 
 
Many IDPs are characterized as promiscuous, meaning they interact with multiple protein 
partners in numerous interactions. Thus, IDPs frequently serve as hubs/nodes in protein 
interaction networks [213, 214]. IDPs can serve in protein hubs by three distinct mechanisms: 1) 
multiple intrinsic disordered regions (IDRs) can serve as docking sites for multiple binding 
partners; 2) multiple IDPs can bind to same structured proteins in the protein hub; and 3) IDRs 
can serve as flexible linkers between separate functional domains and enhance binding 
promiscuity [213, 215]. Protein hubs are essential for the normal functioning of organisms and 
their disruption can be extremely deleterious [216]. Therefore, it is not surprising that many IDPs 
are implicated in human diseases that demonstrate aberrant cell signaling such as cancer, 
cardiovascular disease, and some neurodegenerative diseases [217-219].  For these reasons, IDPs 
would theoretically make attractive drug targets to treat these diseases. However, because these 
disordered proteins do not directly perform catalysis via substrate interaction within enzymatic 
active sites, small molecule inhibitor against IDPs are difficult to generate.  
 
SELENOK is predicted an IDP based on modeling and, as mentioned previously, may be a good 
target for the treatment of metastatic melanoma (see Chapter2). Therefore, design of inhibitors 




Originally, to circumvent this challenge, our laboratory pursued a single domain antibody (sdAb) 
approach to target SELENOK, but due to technical limitations, this approach was abandoned. 
Therefore, we designed a peptide inhibitor based on disrupting the interaction of SELENOK with 
DHHC6, which will be described in detail later. 
 
DHHC family of Protein Acyl-Transferases  
 
Protein palmitoylation is a ubiquitous post translational modification that not only promotes the 
anchorage of proteins in the membrane, but also modulates protein trafficking, vesical fusion, 
organelle inheritance and hydrophobic protein-protein interactions [55]. S-palmitoylation is the 
addition of a saturated 16-carbon fatty acid moiety (or longer chain fatty acids) to sulfhydryl 
groups of cysteine residues via a thioester bond and is reversible [220]. The reversible nature of 
S-palmitoylation permits it to act in a regulatory fashion akin to other reversible post 
translational modifications such as protein phosphorylation and ubiquitination [221, 222] . 
Although the formation of the palmitoyl thioester bond can occur spontaneously in the presence 
of palmitoyl-CoA [223], a genetic screen in Saccharomyces cerevisiae, demonstrated the 
requirement for the first protein acyl-transferase (PAT), Erf2, along with a second protein Erf4, 
for the proper localization of a palmitoylation-dependent RAS protein in the plasma membrane 
[224]. Erf2 (mammalian ortholog DHHC9) contains a conserved domain referred to as the 
DHHC domain, which is shared by numerous genes in eukaryotes only and is integral to the 
palmitoyl transfer reaction. DHHC proteins are found in all eukaryotes (not yet been observed in 
prokaryotes or archaea) and range from 1 to 8 in fungi to greater than 20 in metazoans [222]. All 
DHHC proteins, except for yeast Yn1155W, are predicted to be polytopic integral membrane 
proteins with at least four transmembrane domains [222].  DHHC proteins are expressed in a 
variety of tissues and occupy different subcellular locations, including the Golgi apparatus, the 
ER, and the plasma membrane [225, 226].  
 
The DHHC domain is embedded in a larger motif referred to as the DHHC-Cysteine Rich 
Domain (CRD) [227] with the following consensus sequence: Cx2Cx9HCx2Cx4DHHCx5Cx4Nx3F 




and has been mapped to a cytosolic loop segment [228]. Although it is evident from the data that 
DHHC proteins catalyze the palmitoylation of cytosolic protein substrates, the mechanism by 
which this occurs is not fully understood. Current evidence suggests that the conserved DHHC 
domain is necessary for DHHC protein palmitoylation. For example, all DHHC proteins are 
palmitoylated on a cysteine residue when incubated with palmitoyl-CoA [225, 229] and this 
autopalmitoylation is abolished when one or more cysteine residues in the DHHC motif are 
mutated [229]. Furthermore, the acyl-enzyme intermediate of Erf2 is sensitive to hydroxylamine 
treatment, suggesting a putative labile thioester linkage to cysteine [230]. Taken together, the 
evidence suggests that autopalmitoylation, of which DHHC motif is necessary, represents an 
acyl-enzyme intermediate and is followed by transfer of the palmitoyl group to a target protein.  
 
SELENOK deficiency leads to decreased IP3R palmitoylation and expression in immune and 
melanoma cells, leading to impaired SOCE in these cell types. Because SELENOK is not an 
enzyme, it was clear that SELENOK required one or more partners to enhance the palmitoylation 
of the IP3R. A clue as to which enzyme this could be came from the fact that the DHHC6 is the 
only acyl-transferase containing an SH3 domain, which may interact with SH3BD on 
SELENOK. Indeed, it was demonstrated that SELENOK and DHHC6 interact at the ER 
membrane and this interaction is required for the efficient palmitoylation of the IP3R. DHHC6 is 
one of two DHHC enzymes primary localized in the ER (the other being DHHC4) [231] and is a 
four-pass integral transmembrane protein with the DHHC domain located in the cytosol. In 
addition to its role in palmitoylating the IP3R, DHHC6 also mediates the palmitoylation of the 
E3 ubiquitin-protein ligase AMFR [232] Na+/Ca2+ exchange protein (Calx) [233], transferrin 
receptor protein 1 (TFRC) [234], and may be regulated by another acyl-transferase DHHC16 
[235].  
 
The Src homology 3 domain as potential drug target  
 
Eukaryotic signal transduction utilizes the transient assembly of protein-protein complexes for 
the induction of cellular programs such as survival, proliferation, and migration. The formation 




2 Domain (SH2) and SRC Homology 3 domain (SH3) [236, 237]. While SH2 domains interact 
with phosphotyrosine residues, SH3 domains recognize proline-rich motifs of their partner 
proteins [238, 239]. SH3 domains are approximately 60 amino acids in length and consist of five 
antiparallel β-sheets β-barrel-like structure that form a beta-barrel-like structure [240]. SH3 
domains bind proline-rich peptides with relatively low affinity (Kd = 10
-6 – 10-4 M) and requires 
the minimal consensus sequence PXXP [241, 242]. Specificity is encoded into SH3/SH3BD 
protein interaction by residues adjacent to the protein binding motif itself [200] and manipulation 
of the adjacent residues or the proline residues themselves, can enhance the binding capacity of a 
variety of inhibitors.   
 
Incorporation of non-natural N-substituted peptoids into the SH3 domain, in place of the 
naturally N-substituted proline residues, can increase SH3/SH3BD binding affinity to nanomolar 
levels [243]. Additionally, use of a proline-rich, dimeric peptide inhibitor against the SH3 
containing protein, growth factor receptor-bound protein 2 (Grb2), was shown to be successful in 
disrupting the SH3/SH3BD GRB2/Sos interaction [244]. The dimeric peptide bound Grb2 with 
high affinity (Kd = 40 nM) and was shown to be effective in homogenates of human fibroblast 
cells at a concentration of 1 µM [244]. Most inhibitors in clinical trials are targeted against 
GPCRs and other enzymes. Targeting protein-protein interactions via SH3 domains provides 
new possibility in treating illnesses that are characterized by aberrant intracellular signaling. In 
this chapter, our progress in developing inhibitors that disrupt SELENOK/DHHC6 catalyzed 














Antibody based Inhibition of SELENOK reduces palmitoylation of a DHHC6 target in a 
cell free environment  
 
Inhibition of SELENOK may disrupt SELENOK/DHHC6 mediated palmitoylation of important 
cellular targets and may represent a new therapy for cancers that utilize SOCE for their growth 
and development (see Chapter 2). In order to test the efficacy of various inhibitors to disrupt 
SELENOK/DHHC6 mediated palmitoylation, a protein acyl-transferase (PAT) assay was used. 
The PAT utilizes thin layer chromatography and fluorescence to visualize palmitoylation of a 
peptide derived from the known DHHC6 target protein, CD36 (MGCDRNCK), in the presence 
of SELENOK and various inhibitors (Figure 3.1). Because the assay is performed in an aqueous, 
cell free environment, a water-soluble version of DHHC6 (cDHHC6) was used for all PAT 
assays performed. To establish a premise for the inhibition of SELENOK as an effective drug 
target, an antibody (Ab) specific to the C-terminal portion of SELENOK was tested for its ability 
to inhibit SELENOK/DHHC6 mediated palmitoylation. SELENOK Ab treatment reduced the 
rate of SELENOK/DHHC6 mediated palmitoylation to levels equivalent to palmitoylation rates 
in the absence of SELENOK (Figure 3.2A-B). Furthermore, a non-specific isotype matched Ab 
had no effect on protein palmitoylation (Figure S3.1), suggesting that the reduction in 
palmitoylation observed was due to disruption of SELENOK specifically. Because protein thiols 
can be palmitoylated nonenzymatically in the presence of palmitoyl-CoA [245], we tested 
palmitoylation of CD36 in the absence of cDHHC6. However, without cDHHC6 protein 
palmitoylation was eliminated in this assay (Figure S3.2).  
 
Next, because the functional domain of SELENOK for regulation of palmitoylation is located 
near the C-terminus (a.a. 81-93), including the biologically active Sec residue (a.a 92), inhibition 
of SELENOK may be epitope specific. Therefore, an N-terminal version of SELENOK Ab was 
compared to the C-terminal based Ab in terms of inhibitory capacity. Surprisingly, the N-
terminal antibody reduced palmitoylation rates to the same extent as the C-terminal antibody 




SELENOK, resulting in a disruption of the SELENOK/DHHC6 interaction. Taken together, the 
data suggests that inhibitors that can bind SELENOK may interfere with SELENOK/DHCC6 
protein palmitoylation. 
 
Recombinant SELENOK based inhibitor reduces palmitoylation  
 
Because inhibition of SELENOK by antibody specific binding decreased the functional role of 
SELENOK in a cell free environment, we next asked if a peptide based inhibitory approach was 
feasible. SELENOK interacts with DHHC6 via an SH3/SH3BD interaction  [52], therefore a 
short peptide (80 a.a) was designed with a similar primary amino acid sequence to SELENOK 
that included the proline rich SH3BD but lacked the biologically active functional domain 
(Figure 3.4).  
 
Recombinant inhibitory peptide was purified from E. coli lysates and tested using the same 
palmitoylation assay as described above. Surprisingly, the purified inhibitory peptide increased 
SELENOK/DHHC6 mediated palmitoylation of CD36 above control levels and a mutated, 
putatively catalytically dead version of DHHC6 (DQHR) demonstrated palmitoylation rates 
equivalent to control (Figure 3.5A-C). These results indicate that either the inhibitory peptide 
interacts SELENOK/DHHC6 to enhance protein palmitoylation or impurities from the 
purification process of the inhibitor are interfering with the palmitoylation reaction. To examine 
the latter possibility, SDS page and Coomassie blue staining were performed for the inhibitor 
and DHHC6 (which is purified using a similar method). Results showed an abundance of 
proteins that did not correspond to the estimated size for DHHC6 (~ 26 kDa) or inhibitor (~10 
kDa) (Figure 3.6). Efforts were made to increase the specificity of the purification process which 
resulted in substantially cleaner product for both DHHC6 and inhibitor (Figure 3.7A-B). The 
newly purified components were tested in the palmitoylation assay and the results demonstrated 
that incubation of purified inhibitor with SELENOK/DHHC6 reduced the rate of palmitoylation 
compared to control (Figure 3.8A-B). These results suggest that purified recombinant peptide 
could inhibit SELENOK/DHHC6 mediated palmitoylation but purification of the inhibitor or 





SELENOK inhibitor interacts physically with recombinant cDHHC6 
 
Technical complications surrounding the purification of recombinant peptides led us to pursue a 
synthetic approach to generate inhibitory compounds. Because the cytosolic portion of 
SELENOK is predicted to be intrinsically disordered [70], misfolding issues in the absence of 
cellular folding machinery may not be an issue here. Therefore, an inhibitor of SELENOK was 
synthesized with the same primary amino acid sequence as recombinant SELENOK (Figure 3.4) 
but with the functional domain for the regulation of palmitoylation excluded. Also, the inhibitor 
peptide included the proline rich SH3BD that in concert with flanking amino acids, allows for 
SELENOK/DHHC6 interaction. This approach may disrupt SELENOK/DHHC6 mediated 
palmitoylation by acting as a competitive inhibitor and abrogating full-length SELENOK 
mediated palmitoylation of the IP3R. In addition, a control peptide was synthesized that contains 
the proline rich SH3BD mutated to 7 alanine residues that is putatively sufficient to disrupts 
peptide/DHHC6 binding (Figure 3.4). 
 
As mentioned previously, SELENOK interacts with DHHC6 via an SH3/SH3BD motif. 
Therefore, to test if the synthetic inhibitory peptide can physically bind to cDHHC6 and if the 
SH3BD is necessary, co-Immunoprecipitation was performed. The results indicated that the 
synthetic inhibitor and the control peptide both interact with cDHHC6 (Figure 3.9). This 
suggests that the SELENOK inhibitor can bind cDHHC6 but the SH3BD is not necessary with 
the concentrations used. The overall specificity is likely a composite of the SH3BD and flanking 
amino acids, therefore, mutating the amino acids flanking the SH3BD and adjusting the 
concentration of control peptide/DHHC6 may elucidate what regions are sufficient for 
peptide/DHHC6 binding. Finally, the synthetic inhibitor peptide was tested for its ability to 
reduce SELENOK/DHHC6 mediated palmitoylation in a cell free system. Consistent with the 
co-Immunoprecipitation results, inhibitor peptide reduced palmitoylation of a DHHC6 target and 
the control peptide also reduced palmitoylation rates (Figure 3.10). This results suggest that the 
synthetic inhibitor and control peptide can bind DHHC6 and disrupt DHHC6/SELENOK 





CPP containing SELENOK inhibitor can translocate through the plasma membrane.   
 
Because SELENOK is an intracellular target, any potential drug that targets SELENOK must be 
able to enter the cell to interfere with the biological function of SELENOK. To this end, we 
attached the CPP, penetratin, to the SELENOK inhibitor peptide (Fig 3.4). To test if attachment 
of this CPP was sufficient to allow translocation of inhibitor through the plasma membrane, 
human melanoma cells were treated with inhibitor or a vehicle control (v.c.) and subsequently 
stained for the presence of intracellular SELENOK inhibitor. Originally, the 6×His tag present 
on the inhibitor was the domain used to detect the presence of intracellular inhibitor, but non-
specific background staining could not be distinguished from 6×His tag signal (Figure S3.3). 
Therefore, an antibody specific for the TEV cleavage site of the SELENOK inhibitor was used 
and intracellular inhibitor was detected in the melanoma cells treated with the inhibitor and not 




















Discussion and future directions 
 
The targeting of intracellular proteins that support tumor growth and progression, including 
components of SOCE, has demonstrated some limited success in the treatment of certain cancers 
[246]. However, tumor cells can rapidly develop resistance [247] and therefore the discovery of 
new drug targets is needed. The data presented here shows for the first time that it is possible to 
target SELENOK with either immunotherapy or peptides that can interact with the SELENOK 
protein and limit its biological function. SELENOK may be an attractive protein target for the 
treatment of cancers that utilize SOCE for their growth and proliferation as it is critical for the 
proper expression of an important SOCE component, the IP3R Ca2+ channel. Importantly, IP3R 
mediated Ca2+ flux is upstream of multiple Ca2+ dependent signaling pathways that can become 
constitutively activated by oncogenic mutations in a variety of their individual components such 
as BRAF [141]. Thus, inhibiting SELENOK may have multiple beneficial downstream effects by 
reversing calcium signaling remodeling in tumor cells. 
 
The efficacy of antibody derived therapies that can act as inhibitors of intracellular protein 
targets was previously demonstrated by experiments including sequestration of an HCV viral 
protein that inhibited viral replication [194] or targeting of an F-actin capping protein, CapG, that 
reduced breast cancer metastasis [248]. Both treatments utilized sdAbs (described in the 
introduction) to bind and biologically inhibit their respective targets. The disruption of 
SELENOK/cDHHC6 mediated palmitoylation with an antibody specific to SELENOK suggest 
the possibility of targeting SELENOK with some form of immunotherapy, including sdAbs. 
Indeed, we originally planned to use sdAbs in combination with the CPP penetratin to target 
intracellular SELENOK in melanoma, but for technical reason we were unable to pursue this 
route. Interestingly, either an antibody raised against the C-terminus or the N-terminus displayed 
an ability to inhibit SELENOK/cDHHC6 mediated palmitoylation. This was surprising in that 
the functional domain of SELENOK (a.a. 82-94) which includes the biological relevant Sec 
residue (see Figure 1.1 and 1.3) is located proximal to the C-terminus and thus only the C-
terminus raised antibody was expected to reduce rates of palmitoylation. Perhaps due to the 




resulted in steric interference that prevented SELENOK/cDHHC6 interaction and a resultant 
reduction in palmitoylation of the target peptide. Another possibly may be that the aqueous, cell-
free environment that the reaction takes place in produces results that may not occur in vivo and 
thus, N-terminal SELENOK antibody interference may be an artifact of the experimental design. 
Further investigation utilizing additional antigenic epitopes of SELENOK may help to solve this 
problem. 
 
Targeting SH3 domains on proteins involved in signal transduction, to specifically prevent 
protein-protein interaction has been considered for various disease states [249]. SH3 domains 
mediate signal transduction by providing platforms for disparate proteins to interact and 
therefore can be thought of as adaptor proteins. Because SELENOK and DHHC6 interact via an 
SH3/SH3BD arrangement the inhibitor designed to disrupt this interaction included the SH3BD 
of SELENOK and the surrounding residues. This may allow the inhibitor to act as a competitive 
inhibitor in regard to the SELENOK/DHHC6 complex. As shown by the co-
Immunoprecipitation data, the SELENOK based inhibitor was able to physically interact with 
cDHHC6, but the control peptide, which does not contain the proline rich SH3BD, was also able 
to physically interact with cDHHC6. This may indicate several possibilities: 1) SELENOK and 
DHHC6 do not require an SH3/SH3BD motif for their interaction; 2) residues flanking the 
SH3BD contribute to SELENOK/DHHC6 interaction; or 3) the high concentrations and close 
proximity due to the artificial environment of the cell free reaction is responsible for non-specific 
binding that would not occur in vivo. The first possibility is unlikely in that experiments 
performed where the SH3BD of SELENOK was deleted, resulted in the abrogation of 
SELENOK/DHHC6 interaction as observed by co-Immunoprecipitation and in vitro fluorescent 
based colocalization [52]. The second possibility is interesting because the residues that flank 
SH3 domains provide some form of specificity for SH3/SH3BD interactions [250], which 
implies that these amino acids modulate the local energetics at the entire binding interface. 
Planned studies by our group will involve truncation of the inhibitor peptide to its smallest, 
effective version. This may help elucidate the importance of the residues flanking the SH3BD. 
The third possibility can be tested by investigating colocalization, of the inhibitor and DHHC6 in 





The immunotherapies and SH3 based peptides described above are relatively large and 
hydrophilic, which makes their delivery inside cells challenging. Attachment of CPPs can 
enhance translocation of these drugs across biological membranes. For this reason, the design of 
the SELENOK inhibitor included the amino acid sequence for the CPP, penetratin, near the N-
terminus. The confocal microscopy results seem to indicate that the inclusion of the penetratrin 
motif is sufficient to allow penetratin linked inhibitor to enter melanoma cells in vitro. However, 
other studies have demonstrated that the staining and fixation process of cells, for visualization 
of CPP-cargo entry into cells, can produce false positives [251]. Therefore, further investigation 
is requited to determine if penetratin or more/other CPPs is necessary to bring SELENOK based 
inhibitor cargo into cells.  
 
In addition to the experiments planned for determining the smallest portion of SELENOK based 
inhibitor that can optimally inhibit SELENOK/DHHC6 based palmitoylation, we are planning on 
experiments that can test SELENOK/DHCC6 using thermophoresis and exploring new avenues 
for the design of SELENOK inhibitors. One of these new techniques for drug discovery is known 
as “tethering” ([252]). Tethering is a method of drug discovery that does not rely noncovalent 
interactions between target protein and small-molecule ligands alone, but instead uses a library 
of disulfide-containing fragments that form a disulfide bond with a cysteine residue of the target 
protein. This brings the fragments in proximity to the target protein and allows for the use of 
relatively little protein (10 – 50 mg) to screen more than 10,000 fragments. 
 
Overall, the novel data demonstrating that SELENOK deficiency inhibits the progression of 
melanoma tumor cells in vitro and in vivo and the observation SELENOK can be targeted and 
rendered biologically inert by immunotherapy or peptide fragment application, supports further 
consideration for SELENOK as a potential therapeutic target for melanoma and SOCE 















































Primary antibodies for immunofluorescence included rabbit monoclonal anti-TEV (Invitrogen, 
PA1-119) and mouse-monoclonal FITC labelled anti-His (Miltenyi biotec, 130-098-808). Goat-
anti-rabbit immunofluorescence secondary Alexafluor595 antibody was purchased from 




In a microcentrifuge tube, 10 µL of recombinant cDHHC6 and 5 µL of the synthesized 
inhibitor/control peptide were combined with 5 uL of anti-TEV antibody and incubated 
overnight at 4 ºC. The next day, 100 uL of Protein A resin slurry (Thermo Scientific, 20365) was 
added to the antigen-antibody complex and incubated with gentle shaking for 2 h at room 
temperature. The reaction mixture was washed by adding 0.5 mL of 25mM Tris, 150mM NaCl; 
pH 7.2 and centrifuged for 2 min at 2500 × g. The wash step was repeated twice and a final wash 
with 0.5 mL dH2O was performed, following by centrifugation for 3 min at 2500 × g. To elute 
the immune complex, 50 uL of Electrophoresis Loading Buffer (Bio-Rad) was added to the 
complex-bound resin and incubated for 5 min at 95 ºC. After incubation, the reaction mixture 
was centrifuged for 3 min at 2500 × g and the supernatant was collected and used immediately 
for SDS-PAGE.  
 
In order to determine the size and band position for each protein component, recombinant 
cDHHC6, inhibitor, control peptide, and TEV were loaded into separate wells in addition to the 
immune complexes described above. After protein separation by SDS-PAGE the gel was stained 
by incubation with 50 mL GelCode Blue Safe Protein Stain (Thermo Fisher) for 1 h and de-
stained overnight with ultrapure H2O. Pictures of the gel were recorded using a Gel logic 200 







The validated human melanoma cell line, SK-MEL28, was obtained from the University of 
Hawaii Cancer Center. The cells were cultured in RPMI media with 10% fetal bovine serum and 
1% Antibiotic-Antimycotic (all from GIBCO/ThermoFisher) and grown to 90 confluency. Cells 
were then trypsonized and seeded onto 18mm round microscope glass cover slides in a 12-well 
plate. Cell were washed with PBS and incubated with 2% PFA in PBS for 10 min on ice to fix 
the cells. After 3 washes with PBS, cells were then permeabilized by incubation with 0.1% 
Triton X in PBS for 3 min at room temperature. Cells were washed 3 more times with T-PBS 
and incubated with 5% goat serum in T-PBS for 1h. Next, cells were incubated with anti-TEV 
antibody in T-PBS with 5% goat serum for 1 h at room temperature. Cells were then washed 
three times with T-PBS and incubated with Alexafluor595 secondary antibody for 45 min at 
room temperature and protected from light. Finally, three more washes with T-PBS were 
performed and cells were mounted and the nuclei stained using VECTASHIELD mounting 
medium with DAPI (VECTOR laboratories). Images were obtained using a Leica Microsystems 
LAS AF TCS SP5 confocal microscope.  
 
Recombinant inhibitor design and protein purification  
 
The recombinant inhibitor of SELENOK and catalytically dead DQHR were both generated by 
VectorBuilder Inc. and encoded in the bacterial protein expression vector pBAD; provided in the 
bacterial cloning host Stbl3. The pBAD vector utilizes an arabinose-based operon and therefore 
pilot studies were performed that determined the optimal arabinose percentage for protein 
induction to be 0.002% arabinose in LB broth.  Bacterial cultures were grown overnight at 37 °C 
in LB broth and 0.002% arabinose was added when bacterial cultures reached an OD600 = 0.5 and 
grown for an additional 4 h. To pellet the bacteria, cultures were centrifuged at 10,000 × g for 10 
min and pellets were lysed by incubation with 50 nM NaH2PO4, 300 mM NaCl, 20 mM 
imidazole buffer with 1 mg/mL lysozyme, 10 µg/mL RNase, and 5 µg/mL DNase for 30 in at 4 
°C. Additionally, cells were further lysed using a FB50 Fisher Scientific probe sonicator using 




incubated with 4 mL of Ni-NTA 50% slurry in methanol for 1h at 4 °C on a rotary shaker set at 
200 rpm. The lysate-Ni-NTA mixture was loaded into a Pierce Centrifuge Column (Thermo 
Fisher) and supernatant was allowed to flow through. The column was washed twice with 50 nM 
NaH2PO4, 300 mM NaCl, 20 mM imidazole buffer and eluted in twenty 100 µL fractions using 
50 nM NaH2PO4, 300 mM NaCl, 250 mM imidazole. Elution fractions were analyzed using 
SDS-PAGE and GelCode blue safe protein stain was used to determine the elution fractions that 
contained the recombinant protein of interest. These fractions were recombined and dialyzed 
overnight in 2 L of PBS at 4 °C to removed excess imizadole and stored at -20 °C.  
 
Protein acyl-transferase assays  
 
For all protein acyl-transferase assays a cytosolic version of DHHC6 termed cDHHC6 was used. 
cDHHC6 was generated by cloning the two functional cytosolic domains of DHHC6 connected 
by a flexible linker domain (GGGSGGGSGGGS) into a pET-14b His-tagged expression vector 
(GenScript, Piscataway, NJ). cDHHC6 was purified using a Ni-NTA (G Biosciences) agarose 
column and stored in aliquots at -20 ˚C. Recombinant SELENOK was obtained from the 
laboratory of Sharon Rozovsky (University of Delaware). FITC-labeled fluorescent peptide 
corresponding to the N-terminal dicysteine palmitoylation consensus sequence of CD36 
(MCDRNCK) was purchased from Peptide 2.0 (Chantilly, VA). NBD labeled Palmitoyl-CoA 
was purchased from Peptide 2.0 (Chantilly, VA). Recombinant SELENOK inhibitor was 
purchased from (VectorBuilder) and purified as described in recombinant inhibitor design and 
protein purification section. Synthetic inhibitor and control peptide was purchases from 
AbClonal (Woburn, MA).Prior to protein acyl-transferase assay the FITC-labeled peptide (1 
mM) was treated with 10 mM DTT at room temp. for 1 hr. to reduce disulfide linked dimers. 
Additionally, SELENOK was incubated with cDHHC6 for 1 hr. with the following treatments 
Ab, inhibitor, PBS. Next, the reaction mixtures and reduced peptides were added to 50 mM 
MES, pH 7.4 containing 0.05% DDM and 10 µM NBD-labelled Palmitoyl-CoA to yield a final 
concentration of 10 µM FITC-labeled peptide and incubated at 30 ˚C for 2 to 60 min. After 
reaction completion at desired time point, 10 uL of reaction mixture were collected and stored on 




resolved using a 40% acetonitrile mobile phase. Fluorescent images were obtained using a 
Kodak uv illuminator with a Gel Logic 200 Imaging System. ImageJ was used to measure the 
fluorescent intensity of the FITC-labelled peptide and the palmitoylated FITV-labelled peptide to 






































Figure 3.1 Design of Thin layer chromatography-based protein acyl-transferase assay. 
Schematic of protein acyl-transferase assay (i.e., palmitoylation assay). Assay utilizes 
fluorescence as a read out for rate of palmitoylation where the palmitate donor, palmitoyl-CoA, 
is fused with the fluorochrome nitrobenzoxadiazole (NBD) 
on the palmitate moiety and the target of palmitoylation CD36, is labelled with the fluorochrome 
fluorescein isothiocyanate (FITC). Palmitoylated FITC-CD36 migrates to a lesser extent than 










                      
 
Figure 3.2 A SELENOK specific antibody can inhibit the rate of SELENOK/DHHC6 
palmitoylation in a cell free system. Results of protein acyl-transferase assay with or without 
SELENOK protein present. (A) Image of uv illuminated TLC plate demonstrates reduced 
palmitoylation when reaction mixture does not include SELENOK or includes an antibody 
specific to SELENOK. (B) Graph represents relative rate of palmitoylation from three 
independent experiments. No blocking refers to no antibody present. Results are expressed as 









Figure 3.3 Both C-terminal and N-terminal SELENOK antibodies inhibit 
SELENOK/DHHC6 mediated palmitoylation. Results of protein acyl-transferase assay with 
antibodies specific to separate epitopes on SELENOK. (A) Image of uv illuminated TLC plate 
comparing palmitoylation at various time points for the two epitope specific antibodies that bind 
SELENOK. (B) Graph displaying palmitoylation rate of C-terminal antibodies (SELENOK (c-
term)) and N-terminal antibodies (SELENOK (n-term)). Both SELENOK specific antibodies 
















Figure 3.4 SELENOK inhibitor and control peptide are based on the SH3 binding domain 
of SELENOK. Top: relevant primary amino acid sequence of SELENOK. Middle: primary 
amino acid sequence of the SELENOK inhibitor. Bottom: primary amino acid sequence of the 
control peptide. Yellow highlighted area shows the TEV (Tobacco etch virus) cleavage site, 
green highlighted area shows the penetratin amino acid sequence, and the red highlighted area 












Figure 3.5 Purified inhibitor enhances SELENOK/DHHC6 mediated palmitoylation in a 
cell free system. Results of protein acyl-transferase assay comparing a recombinant inhibitor of 
SELENOK with a SELENOK specific antibody. (A)  Image of uv illuminated TLC plate with the 
groups organized according to separate time points. DQHR refers to the putative catalytically 
dead version of DHHC6, Ab = anti-SELENOK antibody, inh = inhibitor, and vc = vehicle 
control. (B) Image of uv illuminated TLC plate with the groups organized according to group. 
(C) Graph demonstrating rate of palmitoylation derived from images above. Inhibitor increased 
palmitoylation rate compared to control and DQHR demonstrated an equal rate of palmitoylation 












Figure 3.6 Purification of Recombinant proteins contains an abundance of non-specific 
bands. SDS-PAGE and Coomassie blue staining of recombinant inhibitor and cDHHC6. Protein 
ladder for determining protein size by position (left). Both inhibitor and cDHCC6 demonstrate 
















Figure 3.7 Increased specificity of recombinant proteins under new purification conditions. 
SDS-PAGE and Coomassie blue staining of recombinant inhibitor and DHHC6 after protein 
purification. (A) SDS-PAGE for purified inhibitor. Elution fraction number refers to 100 µL 
fractions obtained sequentially from nickel-column during protein purification. Arrow points out 
predicted size of inhibitor (~ 12 kDa). Note the lack of non-specific bands. (B) SDS-PAGE for 
purified cDHHC6. Flow-through (FT), W1 (wash 1), W2 (wash 2), W2 (wash 3), and F 
(cDHHC6 lane). Arrow points out predicted size of cDHHC6 (~ 26 kDa). Some non-specific 










Figure 3.8 Highly specific purified recombinant SELENOK inhibitor reduces 
SELENOK/DHHC6 palmitoylation. Results of protein acyl-transferase assay with or two new 
elution batches of recombinant SELENOK inhibitor.  (A) Image of uv illuminated TLC plate. 
Numbers after SELENOK inhibitor represent various elution fractions. (B) Graph showing slight 
reduction rate of palmitoylation for SELENOK (11) and stronger inhibition of palmitoylation 











Figure 3.9 Inhibitor of SELENOK and control peptide physically interact with DHHC6. 
Image of results from co-Immunoprecipitation assay. cDHHC6 and synthetic SELENOK 
inhibitor or control peptide (control) lacking an SH3BD were incubated for 18 h with TEV 
antibody and subsequently incubated with protein A coated agarose beads for 2 h. Proteins were 
then separated using SDS-PAGE and stained with Coomassie blue to detect protein interaction. 
TEV antibody, Inhibitor, control, and cDHHC6 were run by themselves to determine band 








Figure 3.10 Synthetic SELENOK inhibitor reduces SELENOK/DHHC6 palmitoylation. 
Results of protein acyl-transferase assay with synthetic inhibitor of SELENOK/DHHC6 and 
control peptide. (A) Image of uv illuminated TLC plate showing palmitoylation at various time 
points. (B) Graph showing slight reduced palmitoylation rates for inhibitor peptide and control 








Figure 3.11 CPP containing SELENOK inhibitor can penetrate through cell membrane. 
Confocal microscopy image of a single SK-MEL28 cell. SK-MEL28 cells were incubated with 
either PBS vehicle control (top) or SELENOK inhibitor (bottom) for 1 h. Cells were stained with 
an Ab specific for the TEV cleavage motif which is linked to the SELENOK inhibitor. Results 









Figure S3.1 IgG isotype control has no effect on SELENOK/DHHC6 mediated 
palmitoylation. Graph showing palmitoylation rates with SELENOK antibody treatment 
(SELENO Ab (c-term)), or an isotype matched antibody control (isotype), or treatment with PBS 
vehicle control (vc). SELENOK antibdy reduced rates of palmitoylation compared to vehicle or 














Figure S3.2 cDHHC6 is required for palmitoylation in the presence of palmitoyl-CoA. 





Figure S3.3 Staining for intracellular SELENOK inhibitor with 6×His antibody has non-
specific nuclear targets. SK-MEL28 cells were incubated with either PBS vehicle control (top) 
or SELENOK inhibitor (bottom) for 1 h. Cells were stained with an antibody specific for 6×His 
tag which is linked to the SELENOK inhibitor. Results demonstrate nonspecific staining of 
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